US20030091654A1 - Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols - Google Patents
Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols Download PDFInfo
- Publication number
- US20030091654A1 US20030091654A1 US10/319,328 US31932802A US2003091654A1 US 20030091654 A1 US20030091654 A1 US 20030091654A1 US 31932802 A US31932802 A US 31932802A US 2003091654 A1 US2003091654 A1 US 2003091654A1
- Authority
- US
- United States
- Prior art keywords
- acid
- alcohol
- chromium
- conjugated
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 82
- 235000014113 dietary fatty acids Nutrition 0.000 title claims abstract description 45
- 239000000194 fatty acid Substances 0.000 title claims abstract description 45
- 229930195729 fatty acid Natural products 0.000 title claims abstract description 45
- 150000004665 fatty acids Chemical class 0.000 title claims abstract description 45
- 150000002191 fatty alcohols Chemical class 0.000 title claims abstract description 36
- 208000035150 Hypercholesterolemia Diseases 0.000 title claims abstract description 9
- 210000000577 adipose tissue Anatomy 0.000 title claims abstract description 9
- 201000001421 hyperglycemia Diseases 0.000 title claims abstract description 8
- 206010022489 Insulin Resistance Diseases 0.000 title claims abstract description 7
- 230000009467 reduction Effects 0.000 title claims description 12
- 238000011282 treatment Methods 0.000 title abstract description 20
- 206010012601 diabetes mellitus Diseases 0.000 title description 17
- 150000001844 chromium Chemical class 0.000 title description 14
- 230000006872 improvement Effects 0.000 title description 6
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims abstract description 80
- 229910052804 chromium Inorganic materials 0.000 claims abstract description 80
- 239000011651 chromium Substances 0.000 claims abstract description 80
- 239000000203 mixture Substances 0.000 claims abstract description 71
- 208000008589 Obesity Diseases 0.000 claims abstract description 19
- 235000020824 obesity Nutrition 0.000 claims abstract description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 98
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 37
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 37
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical group OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 claims description 37
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 claims description 34
- 229940108924 conjugated linoleic acid Drugs 0.000 claims description 34
- 239000002738 chelating agent Substances 0.000 claims description 24
- 229940046374 chromium picolinate Drugs 0.000 claims description 23
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 claims description 23
- 235000001968 nicotinic acid Nutrition 0.000 claims description 19
- 239000011664 nicotinic acid Substances 0.000 claims description 19
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical group CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 18
- 229960003512 nicotinic acid Drugs 0.000 claims description 18
- 229940081066 picolinic acid Drugs 0.000 claims description 18
- 230000000510 mucolytic effect Effects 0.000 claims description 17
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 16
- 240000001746 Betula lenta Species 0.000 claims description 16
- 235000010921 Betula lenta Nutrition 0.000 claims description 16
- 235000002992 Betula pubescens Nutrition 0.000 claims description 16
- 244000308505 Filipendula ulmaria Species 0.000 claims description 16
- 235000016622 Filipendula ulmaria Nutrition 0.000 claims description 16
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 claims description 16
- 241001278097 Salix alba Species 0.000 claims description 16
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 claims description 16
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 16
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 claims description 16
- 229940120668 salicin Drugs 0.000 claims description 16
- 240000007551 Boswellia serrata Species 0.000 claims description 15
- 235000012035 Boswellia serrata Nutrition 0.000 claims description 15
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims description 14
- CUXYLFPMQMFGPL-UHFFFAOYSA-N (9Z,11E,13E)-9,11,13-Octadecatrienoic acid Natural products CCCCC=CC=CC=CCCCCCCCC(O)=O CUXYLFPMQMFGPL-UHFFFAOYSA-N 0.000 claims description 14
- IKYKEVDKGZYRMQ-PDBXOOCHSA-N (9Z,12Z,15Z)-octadecatrien-1-ol Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCO IKYKEVDKGZYRMQ-PDBXOOCHSA-N 0.000 claims description 14
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 claims description 14
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 14
- HPCCGRCEBFBZQP-UHFFFAOYSA-N chromium;pyridine-3-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CN=C1 HPCCGRCEBFBZQP-UHFFFAOYSA-N 0.000 claims description 14
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 14
- UVNRLSCOYBEJTM-UHFFFAOYSA-N linolenic alcohol Natural products CCCCCCCCC=C/CC=C/CC=C/CCO UVNRLSCOYBEJTM-UHFFFAOYSA-N 0.000 claims description 14
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims description 14
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 claims description 11
- 230000004580 weight loss Effects 0.000 claims description 10
- 229910021555 Chromium Chloride Inorganic materials 0.000 claims description 9
- 235000007297 Gaultheria procumbens Nutrition 0.000 claims description 9
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 9
- 229960001680 ibuprofen Drugs 0.000 claims description 9
- 229960000905 indomethacin Drugs 0.000 claims description 9
- 239000004856 Balm of Gilead Substances 0.000 claims description 8
- 244000274847 Betula papyrifera Species 0.000 claims description 8
- 235000009113 Betula papyrifera Nutrition 0.000 claims description 8
- 235000009109 Betula pendula Nutrition 0.000 claims description 8
- 235000010928 Betula populifolia Nutrition 0.000 claims description 8
- 241001520764 Betula pubescens Species 0.000 claims description 8
- 235000003717 Boswellia sacra Nutrition 0.000 claims description 8
- 240000000078 Cedronella canariensis Species 0.000 claims description 8
- 235000012196 Cedronella canariensis Nutrition 0.000 claims description 8
- 239000004863 Frankincense Substances 0.000 claims description 8
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 claims description 8
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 8
- 241001458252 Populus x jackii Species 0.000 claims description 8
- 235000021342 arachidonic acid Nutrition 0.000 claims description 8
- 229940114079 arachidonic acid Drugs 0.000 claims description 8
- 229960002146 guaifenesin Drugs 0.000 claims description 8
- 229960002009 naproxen Drugs 0.000 claims description 8
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 8
- 229960005489 paracetamol Drugs 0.000 claims description 8
- ZUUFLXSNVWQOJW-MBIXAETLSA-N (2e,4e,6e)-octadeca-2,4,6-trienoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C(O)=O ZUUFLXSNVWQOJW-MBIXAETLSA-N 0.000 claims description 7
- FPRKGXIOSIUDSE-SYACGTDESA-N (2z,4z,6z,8z)-docosa-2,4,6,8-tetraenoic acid Chemical compound CCCCCCCCCCCCC\C=C/C=C\C=C/C=C\C(O)=O FPRKGXIOSIUDSE-SYACGTDESA-N 0.000 claims description 7
- UNSRRHDPHVZAHH-YOILPLPUSA-N (5Z,8Z,11Z)-icosatrienoic acid Chemical compound CCCCCCCC\C=C/C\C=C/C\C=C/CCCC(O)=O UNSRRHDPHVZAHH-YOILPLPUSA-N 0.000 claims description 7
- HXQHFNIKBKZGRP-URPRIDOGSA-N (5Z,9Z,12Z)-octadecatrienoic acid Chemical compound CCCCC\C=C/C\C=C/CC\C=C/CCCC(O)=O HXQHFNIKBKZGRP-URPRIDOGSA-N 0.000 claims description 7
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 7
- ADHNUPOJJCKWRT-UHFFFAOYSA-N 2,4-octadecadienoic acid Natural products CCCCCCCCCCCCCC=CC=CC(O)=O ADHNUPOJJCKWRT-UHFFFAOYSA-N 0.000 claims description 7
- UNSRRHDPHVZAHH-UHFFFAOYSA-N 6beta,11alpha-Dihydroxy-3alpha,5alpha-cyclopregnan-20-on Natural products CCCCCCCCC=CCC=CCC=CCCCC(O)=O UNSRRHDPHVZAHH-UHFFFAOYSA-N 0.000 claims description 7
- 235000021294 Docosapentaenoic acid Nutrition 0.000 claims description 7
- 235000021292 Docosatetraenoic acid Nutrition 0.000 claims description 7
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 claims description 7
- HXQHFNIKBKZGRP-UHFFFAOYSA-N Ranuncelin-saeure-methylester Natural products CCCCCC=CCC=CCCC=CCCCC(O)=O HXQHFNIKBKZGRP-UHFFFAOYSA-N 0.000 claims description 7
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 7
- CUXYLFPMQMFGPL-SUTYWZMXSA-N all-trans-octadeca-9,11,13-trienoic acid Chemical compound CCCC\C=C\C=C\C=C\CCCCCCCC(O)=O CUXYLFPMQMFGPL-SUTYWZMXSA-N 0.000 claims description 7
- CUXYLFPMQMFGPL-FWSDQLJQSA-N alpha-Eleostearic acid Natural products CCCCC=CC=C\C=C\CCCCCCCC(O)=O CUXYLFPMQMFGPL-FWSDQLJQSA-N 0.000 claims description 7
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 7
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 7
- IXLCRBHDOFCYRY-UHFFFAOYSA-N dioxido(dioxo)chromium;mercury(2+) Chemical compound [Hg+2].[O-][Cr]([O-])(=O)=O IXLCRBHDOFCYRY-UHFFFAOYSA-N 0.000 claims description 7
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 7
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 7
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 7
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 7
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 7
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 claims description 7
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims description 7
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims description 7
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims description 7
- 229960002733 gamolenic acid Drugs 0.000 claims description 7
- 229960004488 linolenic acid Drugs 0.000 claims description 7
- 235000019988 mead Nutrition 0.000 claims description 7
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 claims description 7
- XSSMKBYYGOUGFP-BBDGQJMTSA-N (2S)-2-amino-3-(1H-imidazol-5-yl)propanoic acid chromium Chemical compound [Cr].OC(=O)[C@@H](N)CC1=CNC=N1.OC(=O)[C@@H](N)CC1=CNC=N1.OC(=O)[C@@H](N)CC1=CNC=N1 XSSMKBYYGOUGFP-BBDGQJMTSA-N 0.000 claims 6
- ADHNUPOJJCKWRT-JLXBFWJWSA-N (2e,4e)-octadeca-2,4-dienoic acid Chemical compound CCCCCCCCCCCCC\C=C\C=C\C(O)=O ADHNUPOJJCKWRT-JLXBFWJWSA-N 0.000 claims 6
- 241000736246 Pyrola Species 0.000 claims 6
- CVCXSNONTRFSEH-UHFFFAOYSA-N docosa-2,4-dienoic acid Chemical compound CCCCCCCCCCCCCCCCCC=CC=CC(O)=O CVCXSNONTRFSEH-UHFFFAOYSA-N 0.000 claims 6
- 230000001737 promoting effect Effects 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract description 15
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 42
- 150000001875 compounds Chemical class 0.000 description 33
- 102000004877 Insulin Human genes 0.000 description 21
- 108090001061 Insulin Proteins 0.000 description 21
- 229940125396 insulin Drugs 0.000 description 21
- 239000011325 microbead Substances 0.000 description 18
- 238000010521 absorption reaction Methods 0.000 description 15
- 230000004190 glucose uptake Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 239000003826 tablet Substances 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 210000002027 skeletal muscle Anatomy 0.000 description 10
- 230000000968 intestinal effect Effects 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229910052751 metal Inorganic materials 0.000 description 8
- 239000002184 metal Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 150000002739 metals Chemical class 0.000 description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- -1 chromium Chemical class 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 235000008216 herbs Nutrition 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 150000003180 prostaglandins Chemical class 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 206010033307 Overweight Diseases 0.000 description 4
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 239000002702 enteric coating Substances 0.000 description 4
- 238000009505 enteric coating Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000001502 supplementing effect Effects 0.000 description 4
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 3
- QJOSVOSTKBUREB-BBDGQJMTSA-K (2s)-2-amino-3-(1h-imidazol-5-yl)propanoate;chromium(3+) Chemical compound [Cr+3].[O-]C(=O)[C@@H](N)CC1=CNC=N1.[O-]C(=O)[C@@H](N)CC1=CNC=N1.[O-]C(=O)[C@@H](N)CC1=CNC=N1 QJOSVOSTKBUREB-BBDGQJMTSA-K 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- 101150018198 COX1 gene Proteins 0.000 description 3
- 101150071146 COX2 gene Proteins 0.000 description 3
- 101100275424 Danio rerio mt-co1 gene Proteins 0.000 description 3
- 101100275428 Dictyostelium discoideum cox1/2 gene Proteins 0.000 description 3
- 240000001238 Gaultheria procumbens Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 229960001582 fenfluramine Drugs 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 229940066491 mucolytics Drugs 0.000 description 3
- 230000003843 mucus production Effects 0.000 description 3
- 239000012053 oil suspension Substances 0.000 description 3
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 3
- 229960000395 phenylpropanolamine Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229940107161 cholesterol Drugs 0.000 description 2
- 150000001845 chromium compounds Chemical class 0.000 description 2
- 239000011636 chromium(III) chloride Substances 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 235000006486 human diet Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229960003562 phentermine Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- OYHQOLUKZRVURQ-UHFFFAOYSA-N 9,12-Octadecadienoic Acid Chemical compound CCCCCC=CCC=CCCCCCCCC(O)=O OYHQOLUKZRVURQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 229940124638 COX inhibitor Drugs 0.000 description 1
- 101100496968 Caenorhabditis elegans ctc-1 gene Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229910021556 Chromium(III) chloride Inorganic materials 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 208000036818 High risk pregnancy Diseases 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100221647 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-1 gene Proteins 0.000 description 1
- YVVONORJTFWCED-UHFFFAOYSA-N O=C(O)C1=CC=CN=C1.O=C(O)C1=NC=CC=C1 Chemical compound O=C(O)C1=CC=CN=C1.O=C(O)C1=NC=CC=C1 YVVONORJTFWCED-UHFFFAOYSA-N 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-M O=C([O-])C1=NC=CC=C1 Chemical compound O=C([O-])C1=NC=CC=C1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 1
- 101150062589 PTGS1 gene Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000161288 Populus candicans Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000030538 Thecla Species 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229960000359 chromic chloride Drugs 0.000 description 1
- 235000007831 chromium(III) chloride Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000081 effect on glucose Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000001457 metallic cations Chemical class 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100001078 no known side-effect Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000011903 nutritional therapy Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- AKMJJGSUTRBWGW-UHFFFAOYSA-N pyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 AKMJJGSUTRBWGW-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000026313 regulation of carbohydrate metabolic process Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000001562 ulcerogenic effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/76—Salicaceae (Willow family), e.g. poplar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Definitions
- compositions and methods for the treatment of type 1 diabetes, reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia relate to compositions and methods for the treatment of type 1 diabetes, reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia.
- compositions comprising chromium complexes in combination with conjugated compounds such as isomers of conjugated fatty acids or conjugated fatty alcohols.
- Diabetes is a chronic metabolic disorder which afflicts 16 million people in the United States, over one and one half million of whom have its most severe form, childhood diabetes (also called juvenile, type 1 or insulin-dependent diabetes). Insulin-dependent diabetes appears suddenly, most often in children and young adults, and progresses rapidly. In this form, the pancreas ceases to manufacture insulin, a hormone necessary to convert the food we eat into energy for the body. In the United States, diabetes is the fourth leading cause of death, killing more than 162,000 people each year. Notably, the mortality rate of patients with insulin-dependent diabetes increases dramatically after 15 years of disease duration. In addition, virtually every major organ system in the body is damaged by diabetes. Complications can include blindness, kidney failure, heart disease, stroke, amputation of extremities, loss of nerve sensation, early loss of teeth, high-risk pregnancies and babies born with birth defects.
- Insulin resistance is characterized by reductions of glucose uptake in skeletal muscle.
- insulin injection is the only treatment method available for the over 1.5 million type 1 diabetics and becomes the eventual course of treatment for many of the more than 16 million type 2 diabetics in the United States.
- Nutritional therapies that positively impact glucose uptake in the face of insulin insufficiency would have a major impact on the long term treatment costs associated with diabetic care.
- Chromium picolinate is reported to produce modest weight loss and changes in body composition (Kaats, 1998, Cefalu, 1999). Chromium is a nutritionally essential trace element. The essentiality of chromium in the diet was established in 1959 by Schwartz, as cited in Present Knowledge in Nutrition , page 571, fifth edition (1984, the Nutrition Foundation, Washington, D.C.). Chromium depletion is characterized by the disturbance of glucose, lipid and protein metabolism and by a shortened lifespan. Chromium is essential for optimal insulin activity in all known insulin-dependent systems (Boyle et al., Southern Med. J. 70:1449-1453, 1977). Insufficient dietary chromium has been linked to both maturity-onset diabetes and to cardiovascular disease.
- the principal energy sources for the body are glucose and fatty acids. Chromium depletion results in biologically ineffective insulin and compromised glucose metabolism. Under these conditions, the body must rely primarily on lipid metabolism to meet its energy requirements, resulting in the production of excessive amounts of acetyl-CoA and ketone bodies. Some of the documented acetyl-CoA is diverted to increased cholesterol biosynthesis, resulting in hypercholesterolemia. Diabetes mellitus is characterized in large part by glycosuria, hypercholesterolemia, and often ketoacidosis. The accelerated atherosclerotic process seen in diabetics is associated with hypercholesterolemia (Boyle et al., supra.).
- Chromium functions as a cofactor for insulin. It binds to the insulin receptor and potentiates many, and perhaps all, of its functions (Boyle et al., supra.). These functions include, but are not limited to, the regulation of carbohydrate and lipid metabolism. ( Present Knowledge in Nutrition , supra. at p. 573-577).
- the introduction of inorganic chromium compounds per se into individuals is not particularly beneficial. Chromium must be converted endogenously into an organic complex or must be consumed as a biologically active molecule. Only about 0.5% of ingested inorganic chromium is assimilated into the body ( Recommended Daily Allowances , Ninth Revised Edition, The National Academy of Sciences, page 160, 1980). Only 1-2% of most organic chromium compounds are assimilated into the body.
- U.S. Pat. No. Re. 33,988 discloses that when selected essential metals, including chromium, are administered to mammals as exogenously synthesized coordination complexes of picolinic acid, they are directly available for absorption without competition from other metals.
- This patent describes a composition and method for selectively supplementing the essential metals in the human diet and for facilitating absorption of these metals by intestinal cells. These complexes are safe, inexpensive, biocompatible and easy to produce.
- These exogenously synthesized essential metal coordination complexes of picolinic acid pyridine-2-carboxylic acid
- M represents the metallic cation and n is equal to the cation's valence.
- n is equal to the cation's valence.
- M represents the metallic cation and n is equal to the cation's valence.
- M represents the metallic cation and n is equal to the cation's valence.
- M represents the metallic cation and n is equal to the cation's valence.
- n is equal to the cation's valence.
- chromium picolinates disclosed include chromic monopicolinate and chromic dipicolinate.
- the U.S. Recommended Daily Intake (RDI) of chromium is 120 ⁇ g.
- International Patent Application No. WO96/35421 discloses the use of high doses of chromic tripicolinate (providing 1,000-10,000 ⁇ g chromium/day) for reducing hyperglycemia and stabilizing the level of serum glucose in humans with type 2 diabetes.
- U.S. Pat. No. 5,789,401 discloses achromic tripicolinate-biotin composition and its use in lowering blood glucose levels in humans with type 2 diabetes.
- Picolinic acid and nicotinic acid are position isomers having the following structures:
- Nicotinic acid and picolinic acid form coordination complexes with monovalent, divalent and trivalent metal ions and facilitate the absorption of these metals by transporting them across intestinal cells and into the bloodstream.
- Chromium absorption in rats following oral administration of CrCl 3 was facilitated by the non-steroidal anti-inflammatory drugs (NSAIDs) aspirin and indomethacin (Davis et al., J. Nutrition Res. 15:202-210, 1995; Kamath et al., J. Nutrition 127:478-482, 1997).
- NSAIDs non-steroidal anti-inflammatory drugs
- These drugs inhibit the enzyme cyclooxygenase which converts arachidonic acid to various prostaglandins, resulting in inhibition of intestinal mucus formation and lowering of intestinal pH which facilitates chromium absorption.
- compositions for the treatment of diabetes and obesity would be a great boon to subjects suffering from these disease states.
- a new, more effective, less expensive treatment for diabetes and obesity with minimal side effects would be a great benefit to the treatment and prevention of obesity.
- FIG. 1 shows the effect of conjugated linoleic acid (CLA) on glucose uptake in human skeletal muscle culture.
- CLA conjugated linoleic acid
- FIG. 2 graphs the effect of CP+CLA on glucose uptake in human skeletal muscle culture.
- FIG. 3 illustrates the effect of CP+CLA on glucose uptake in human skeletal muscle culture.
- the disclosed invention is directed to compositions and methods for treating insulin-dependent diabetes, non-insulin dependent diabetes, reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia.
- One embodiment of the disclosed invention is a composition that includes at least one chromium complex and a conjugated fatty acid or conjugated fatty alcohol.
- the chromium complex is chromium picolinate or chromium nicotinate.
- the conjugated fatty acid is conjugated linoleic acid.
- the composition optionally includes a chelating agent.
- the chelating agent may be picolinic acid, nicotinic acid, or both.
- compositions are incorporated into a pharmaceutically effective carrier.
- the pharmaceutically effective carrier may be a tablet, capsule, microbead, emulsion, powder, granule, suspension, syrup or elixir.
- the microbead is a sugar beadlet or microcrystalline cellulose beadlet.
- the chromium complex and conjugated linoleic acid are coated on the beadlet.
- the tablet, capsule, or microbead is coated with an enteric coating.
- the chromium complex and conjugated fatty acid or conjugated fatty alcohol are in a ratio of between about 1:666 to about 1:200 (w/w).
- the composition may include at least one of a cyclooxygenase inhibitor, a mucolytic, or a salicin-containing herb.
- the cyclooxygenase inhibitor may be indomethacin, ibuprofen, acetaminophen, or naproxen.
- the salicin-containing herb may include Boswellia serrata (frankincense), Betula lenta (sweet birch), Betula pubescens (white birch), Filipendula ulmaria (meadowsweet), Gautheria procumbens (wintergreens), Polulus balsamifera, Populus jackii (balm of Gilead) and Salix alba (white willow).
- the mucolytic may be guaifenesin.
- Embodiments of the invention provide a method of treating type 1 diabetes in a subject.
- the method of treatment includes administering to a subject a pharmaceutically effective dose of a conjugated fatty acid or conjugated fatty alcohol in conjunction with at least one chromium complex.
- the chromium complex may be chromium picolinate, chromium nicotinate, chromic tripicolinate, chromic polynicotinate, chromium chloride, chromium histidinate, or chromium yeasts.
- the composition further includes at least one chelating agent.
- the chelating agent may be picolinic acid, nicotinic acid, or both.
- a method of treating obesity in a subject is similarly contemplated.
- the method of treatment includes administering to a subject a pharmaceutically effective dose of conjugated fatty acid or conjugated fatty alcohol in conjunction with at least one chromium complex.
- the chromium complex may be chromium picolinate, chromium nicotinate, chromic tripicolinate, chromic polynicotinate, chromium chloride, chromium histidinate, or chromium yeasts.
- the composition further includes at least one chelating agent.
- the chelating agent may be picolinic acid, nicotinic acid, or both.
- the disclosed invention relates to compositions for the treatment of type 1 diabetes.
- these compositions can be administered to reduce or even eliminate the need for administration of insulin in certain patients with type 1 diabetes. Further, they are used in methods for facilitating glucose uptake and utilization by cells. Certain individuals with type 2 diabetes will require insulin.
- the invention also relates to the treatment of type 2 diabetics who require insulin. Additionally, methods for treating obesity and increasing lean body mass are likewise contemplated.
- a primary basis of the present invention is the novel and unexpected discovery that compositions comprising an effective dose of a chromium complex in combination with a conjugated fatty acid or conjugated fatty alcohol produce a synergistic effect on glucose uptake in a subject in need thereof. Additionally, the co-administration of a chromium complex with a conjugated fatty acid or conjugated fatty alcohol, or an isomer thereof, demonstrate a synergistic, weight loss effect.
- conjugated compound refers to a compound having at least a portion that is a hydrocarbon, with at least three consecutive carbon-carbon bonds, such that single and double carbon-carbon bonds are found in an alternating manner. Thus, the compound will include the subunit C ⁇ C—C ⁇ C (hydrogens and other substituents not shown).
- conjugated compounds are fatty acids and fatty alcohols. It should be noted that these di- or poly-unsaturated compounds are referred to herein using the common names of the corresponding naturally-occurring compounds having the same number of carbons and unsaturations.
- conjugated fatty acid also includes isomers of fatty acids and fatty alcohols, as well as any other polyunsaturated compounds which act synergistically with chromium complexes to promote glucose uptake in a subject in need thereof
- Suitable conjugated fatty acids include, without limitation, conjugated versions of linoleic acid, linolenic acid, gamma linolenic acid, arachidonic acid, mead acid, stearidonic acid, alpha-eleostearic acid, eleostearic acid, pinolenic acid, docosatetraenoic acid, 9,12-octadecadienoic acid, octadecatrienoic acid, eicosatetraenoic acid, eicosapentaenoic acid, docosahexaenoic acid, docosapentaenoic acid, and
- the conjugated fatty acid is conjugated linoleic acid (CLA).
- CLA conjugated linoleic acid
- conjugated fatty alcohols includes, without limitation, conjugated versions of linoleic alcohol, linolenic alcohol, gamma linolenic alcohol, arachidonic alcohol, mead alcohol, stearidonic alcohol alpha-eleostearic alcohol, eleostearic alcohol, pinolenic alcohol, docosadienic alcohol, docosatetraenoic alcohol, octadecadienoic alcohol, octadecatrienoic alcohol, eicosatetraenoic alcohol, cicosapentaenoic alcohol, docosahexaenoic alcohol, docosapentaenoic alcohol, and all other diunsaturated and polyunsaturated fatty alcohols.
- the present invention further includes the use of other conjugated compounds having at least 4, 5, 6, 7, or 8 carbon atoms, that functions synergistically with a chromium complex to facilitate glucose uptake and usage by cells. (Such function can be readily assayed, as further described below.)
- the present invention includes alcohols and acids in which one or more of the double bonds result in a cis isomer, as well as those in which one or more of the double bonds result in a trans isomer. In some cases, all the double bonds are cis, while in others they are all trans, and in still other cases they are mixed cis and trans compounds.
- the conjugated fatty acid of the composition is conjugated linoleic acid.
- Conjugated linoleic acid CLA
- CLA Conjugated linoleic acid
- Park et al., 1997 Minimal studies have been performed on human subjects.
- Atkinson et al. there was no effect of CLA alone in obese subjects when added to standard diet and exercise.
- a subgroup of subjects who did not follow the diet and exercise program well, and who gained lean body mass had a reduction in fat mass in the CLA subjects and an increase in fat mass in placebo subjects (Atkinson, communication, 2000).
- CLA CLA may act as a ⁇ -3 agonist
- CLA alters nutrient partitioning within muscles to promote fat oxidation rather than carbohydrate (CHO) oxidation (Park et al., 1999).
- Embodiments of the present invention include compositions which contain a conjugated fatty acid or conjugated fatty alcohol in combination with at least one chromium complex. Additionally, uses of the compositions disclosed herein to treat diabetes and/or obesity are provided. The co-administration of a conjugated fatty acid or conjugated fatty alcohol and at least one chromium complex provides a number of advantages over conventional pharmaceutical regimes for the treatment of diabetes and promotion of weight loss.
- One advantage of the compositions described herein over conventional treatment regimes for diabetes (such as injection of insulin) and weight loss is that compositions comprising a conjugated compound such as a conjugated fatty acid or conjugated fatty alcohol and at least one chromium complex have no known side effects while still providing efficacy in glucose uptake and weight loss.
- FIGS. 1 and 2 are pico Moles per milligram of glucose uptake.
- the unit referred to on the vertical axis of FIG. 3 is the percentage increase in the uptake of glucose in human skeletal muscle culture.
- Basal as used in FIGS. 1 and 2 refers to human skeletal muscle culture without insulin.
- Stimulated indicates human skeletal muscle culture with insulin.
- Those bars on FIGS. 1, 2, and 3 representing Chromium Picolinate (CP) and Conjugated Linoleic Acid (CLA) are measured in nanograms per milliliter.
- CLA in combination with a chromium complex such as chromium picolinate (CP) (as depicted in FIG. 2) significantly increases glucose uptake in human skeletal muscle culture under both basal (without insulin) and stimulated (with insulin) conditions.
- chromium complexes include, without limitation, chromium picolinate, chromic tripicolinate, chromium nicotinate, chromic polynicotinate, chromium chloride, chromium histidinate, and chromium yeasts.
- Chromium picolinate for example, has been shown to produce modest weight loss and changes in body composition.
- compositions of the disclosed invention additionally include an effective dose of conjugated compound such as a conjugated fatty acid or conjugated fatty alcohol, of the type previously described.
- the conjugated fatty acid component of the composition is linoleic acid (CLA).
- CLA linoleic acid
- Suitable forms of CLA include isomers with double bonds at carbons 9, 11; carbons 10,12; or a mixture thereof.
- the compositions include the 10,12 form of CLA to reduce body fat and increase lean body mass.
- the composition will include the conjugated compound at a dose of at least 50% by weight of formulation. More preferably, the effective dose of the conjugated compound for a 70 kg human is between about 100 mg to about 10 grams. In a most preferred embodiment, the effective dose of the conjugated compound is 75 mg, 100 mg, 250 mg, 500 mg, 750 mg, 1000 mg, 2 g, 5 g, 7 g, or 10 g.
- chelating agents are advantageously included in the compositions to facilitate absorption of other ingested chromium as well as other metals including, but not limited to, copper, iron, magnesium, manganese and zinc.
- Suitable chelating agents include picolinic acid, nicotinic acid, or both picolinic acid and nicotinic acid.
- the chromium complexes of the disclosed invention have the same uses as described for chromic tripicolinate in U.S. Pat. Nos. 5,087,623, 5,087,624 and 5,174,156, namely supplementing dietary chromium, lowering blood glucose levels in diabetics, lowering serum lipid levels and increasing lean body mass. Additionally, the chromium complexes of the present invention act to treat symptoms associated with overweight and obesity.
- the chromium complexes are synthetic.
- the synthesis and use of chromium picolinates is described in U.S. Pat. No. Re. 33,988 and U.S. Pat. No. 5,087,623.
- Chromic tripicolinate is available from health food stores, drug stores and other commercial sources.
- the synthesis and use of chromic polynicotinate is described in U.S. Pat. No. 5,194,615.
- the chelating agents such as picolinic acid and nicotinic acid are available from many commercial sources, including Sigma-Aldrich (St. Louis, Mo.) (picolinic acid; catalog No. P5503; nicotinic acid; catalog No. PN4126).
- the ratio of the chromium complex to the chelating agent from about 10:1 to about 1:10 (w/w), more preferably from about 5:1 to about 1:5 (w/w).
- compositions of the disclosed invention are prepared by incorporating the components into a pharmaceutically acceptable carrier, including but not limited to tablets, capsules and microbeads, preferably sugar beadlets or microcrystalline cellulose.
- the chromium complex may be incorporated into a tablet, aqueous or oil suspension, dispersible powder or granule, microbead, emulsion, hard or soft capsule, syrup or elixir.
- the components of the composition may also be administered separately.
- Compositions may be prepared according to any method known in the art for the manufacture of pharmaceutically acceptable compositions and such compositions may contain one or more of the following agents: sweeteners, flavoring agents, coloring agents and preservatives. Tablets containing the active ingredients in admixture with non-toxic pharmaceutically acceptable excipients suitable for tablet manufacture are acceptable.
- “Pharmaceutically acceptable” means that the agent should be acceptable in the sense of being compatible with the other ingredients of the formulation (as well as non-injurious to the individual).
- excipients include inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, such as corn starch and alginic acid; binding agents such as starch, gelatin or acacia; and lubricating agents such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or may be coated with known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period of time. For example, a time delay material such as glyceryl monostearate or glyceryl stearate alone or with a wax may be employed.
- tablets, capsules or microbeads are coated with an enteric coating which prevents dissolution in the acidic environment of the stomach. Instead, this coating dissolves in the small intestine at a more neutral pH. Because certain chromium complexes may be more stable at this neutral pH than at the acidic pH of the stomach, enhanced absorption occurs because the chromium complexes remain substantially intact until they reach the small intestine.
- enteric coated compositions are described by Bauer et al., Coated Pharmaceutical Dosage Forms: Fundamentals, Manufacturing Techniques, Biopharmaceutical Aspects, Test Methods and Raw Materials , CRC Press, Washington, D.C., 1998, the entire contents of which are hereby incorporated by reference.
- Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
- an inert solid diluent for example calcium carbonate, calcium phosphate or kaolin
- an oil medium such as peanut oil, liquid paraffin or olive oil.
- Aqueous suspensions may contain the chromium complexes of the invention in admixture with excipients for the manufacture of aqueous suspensions.
- excipients include suspending agents, dispersing or wetting agents, one or more preservatives, one or more coloring agents, one or more flavoring agents and one or more sweetening agents such as sucrose or saccharin.
- Oil suspensions may be formulated by suspending the active ingredient in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
- the oil suspension may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol.
- Sweetening agent such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation.
- These compositions may be preserved by an added antioxidant such as ascorbic acid.
- Dispersible powders and granules of the invention suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, and one or more preservatives. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
- Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
- sweetening agents such as glycerol, sorbitol or sucrose.
- Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
- the oral formulations described above may also include aspirin (acetylsalicylic acid), other salicylates, or another NSAID such as indomethacin, ibuprofen, acetaminophen, naproxen or any drug capable of inhibiting the cyclooxygenase pathway leading to prostaglandin synthesis.
- aspirin acetylsalicylic acid
- other salicylates or another NSAID
- indomethacin ibuprofen
- acetaminophen acetaminophen
- naproxen any drug capable of inhibiting the cyclooxygenase pathway leading to prostaglandin synthesis.
- the oral compositions may further include mucolytics such as guaifenesin and the like, to inhibit intestinal mucus production, and/or acids such as ascorbic acid, citric acid and the like to lower intestinal pH.
- cox cyclooxygenase
- cox1 cox1
- cox2 cyclooxygenase
- the cox2 isozyme promotes prostaglandin formation at sites of inflammation, but not at other sites such as the gastrointestinal tract.
- relatively selective inhibition of cox 1 facilitates chromic tripicolinate and chromic polynicotinate absorption.
- any inhibitor or cox1 or cox2 can be formulated with the chromic tripicolinate and chromic polynicotinate compositions of the invention.
- Cox inhibitors, acids and mucolytics may also be coadministered with the chromic tripicolinate and chromic polynicotinate compositions of the invention.
- the amount of these drugs formulated with or coadministered with the chromic tripicolinate compositions of the invention are as follows: cox inhibitions, between about 50 mg and 500 mg; mucolytics, between about 10 mg and 250 mg; and acids, between about 50 mg and about 1,000 mg.
- Class I herbs as documented in the American Herbal Products Association's Botanical Safety Handbook (herbs that can be safely consumed when used appropriately), such as Boswelia serrata (frankincense), Betula lenta (sweet birch), Betula pubescens (white birch), Filipendula ulmaria (meadowsweet), Gaultheria procumbens (wintergreens), Populus balsamifera and Populus jackii (balm of Gilead), and Salix alba (white willow) are all salicin-containing plants with salicylate-like properties.
- the compounds and herbs described above all effect gut physiology by inhibiting prostaglandin synthesis, decreasing mucus production, and lowering gastrointestinal pH.
- the inclusion of these compounds, as well as an enteric coating, into the oral chromium picolinate or chromium nicotinate compositions of the invention results in a multicomponent delivery system which allows delivery of these agents to the gastrointestinal tract where they work in concert to facilitate chromium absorption.
- the chromium complex is coated onto microbeads.
- these microbeads are sugar beadlets of various sizes, also known as nonpareils, and are commercially available from, for example, SmithKline Beecham. If the microbeads are to be used to administer the compositions of the invention to diabetic patients, the administration of other types of microbeads, such as microcrystalline cellulose, is preferred. Microcrystalline cellulose is commercially available and can be processed into beadlets of various sizes by micronization, a technique well known in the art. The microbeads are essentially a carrier for the compositions of the invention.
- coated beadlets see, for example, Carstensen, I. T., Pharmaceutical Principles of Solid Dosage Forms , Technonic Publishing Co., Inc., Lancaster, Pa., pp. 228-230, 1993, hereby incorporated by reference.
- Aqueous solutions containing the chromium complexes with or without the chelating agent components such as nicotinic acid and picolinic acid are sprayed onto the microbeads by well known methods. by suspending the microbeads in an up current of air and introducing a fine spray of the active ingredients which form a coating on the outside of the microbeads which is then allowed to dry.
- the desired chromium complex components with or without a chelating agent may be combined into one same solution or applied using separate solutions.
- the coated microbeads can be further coated with a substance to protect the active ingredients coated onto the beads, such as latex.
- the microbeads may be placed in a capsule prior to administration.
- the capsule or the microbeads are coated with an enteric coating to delay dissolution until reaching the small intestine.
- the dosage range of chromium administered to an individual in the form of chromium picolinate, chromium nicotinate, or other chromium complex provides between about 50 and 10,000 micrograms per day of chromium; preferably between about 100 and 1,000 micrograms per day; more preferably, between about 200 and 500 micrograms per day.
- methods of increasing glucose uptake by cells or by organisms, such as mammals and humans, treating insulin-dependent diabetes, reducing body fat, improving insulin sensitivity, reducing hyperglycemia, and reducing hypercholesterolemia with chromium complexes and conjugated compounds such as conjugated fatty acids or conjugated fatty alcohols are contemplated and isomers of fatty acids, as well as isomers of fatty alcohols.
- a subject is administered a pharmaceutically effective dose of a chromium complex.
- the conjugated compound is administered substantially simultaneously with the chromium complex.
- the chromium complex is administered first and then the conjugated compound is added second.
- the conjugated compound is administered first.
- the chromium complex and conjugated compound are administered to a subject within twenty-four hours of each other.
- the chromium complex and conjugated compound are administered within an hour of each other.
- the following examples teach certain methods and compositions for treating diabetes and obesity through the administration of at least one chromium complex in concert with a conjugated compound.
- the subject can advantageously be a vertebrate, a mammal, a bird, and is preferably a human, a cat, or a dog.
- the at least one chromium complex may be administered first, then the conjugated compound.
- the conjugated compound can be administered first, then the chromium complex.
- the composition may optionally include picolinic acid, nicotinic acid, or both picolinic acid and nicotinic acid in combination with a chromium complex and conjugated compound.
- An obese adult human subject is identified.
- the subject is orally administered a tablet containing about 300 ⁇ g chromium as chromium picolinate and 1 gram conjugated linoleic acid twice a day.
- the tablet additionally comprises ibuprofen in a pharmaceutically effective dose of 200 mg.
- a decrease in body mass is observed.
- the chromium picolinate in combination with conjugated linoleic acid synergistically reduce the subject's body mass.
- a subject suffering from insulin-dependent diabetes is identified.
- the subject is orally administered a daily dose of one tablet containing about 500 ⁇ g chromium as chromium nicotinate and 500 mg conjugated linoleic acid.
- a daily dose of one tablet containing about 500 ⁇ g chromium as chromium nicotinate and 500 mg conjugated linoleic acid.
- the chromium nicotinate in combination with linoleic acid act synergistically to improve the subject's glucose tolerance and to treat the subject's diabetes.
Abstract
A composition for treating insulin-dependent diabetes, reducing body fat, improving insulin sensitivity, reducing hyperglycemia, and reducing hypercholesterolemia with at least one chromium complex and a conjugated fatty acid or conjugated fatty alcohol is disclosed. A method of treating a subject suffering from insulin-dependent diabetes by administering a composition that includes at least one chromium complex and a conjugated fatty acid or conjugated fatty alcohol is similarly provided. The administration of a composition containing an effective dose of at least one chromium complex and a conjugated fatty acid or conjugated fatty alcohol for the treatment of obesity is likewise provided.
Description
- This application is a divisional of prior application Ser. No. 09/957,876, filed Sep. 20, 2001, which claims priority to provisional application filed Sep. 21, 2000 having application No. 60/234,474, and provisional application filed Jun. 6, 2001 having application No. 60/296,688, each of which is hereby incorporated by reference.
- 1. Field of the Invention
- The disclosed invention related to compositions and methods for the treatment of
type 1 diabetes, reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia. Specifically, compositions comprising chromium complexes in combination with conjugated compounds such as isomers of conjugated fatty acids or conjugated fatty alcohols. - 2. Description of the Related Art
- Insulin-Dependent Diabetes
- Diabetes is a chronic metabolic disorder which afflicts 16 million people in the United States, over one and one half million of whom have its most severe form, childhood diabetes (also called juvenile,
type 1 or insulin-dependent diabetes). Insulin-dependent diabetes appears suddenly, most often in children and young adults, and progresses rapidly. In this form, the pancreas ceases to manufacture insulin, a hormone necessary to convert the food we eat into energy for the body. In the United States, diabetes is the fourth leading cause of death, killing more than 162,000 people each year. Notably, the mortality rate of patients with insulin-dependent diabetes increases dramatically after 15 years of disease duration. In addition, virtually every major organ system in the body is damaged by diabetes. Complications can include blindness, kidney failure, heart disease, stroke, amputation of extremities, loss of nerve sensation, early loss of teeth, high-risk pregnancies and babies born with birth defects. - Insulin resistance is characterized by reductions of glucose uptake in skeletal muscle. Currently, insulin injection is the only treatment method available for the over 1.5 million
type 1 diabetics and becomes the eventual course of treatment for many of the more than 16 million type 2 diabetics in the United States. Nutritional therapies that positively impact glucose uptake in the face of insulin insufficiency would have a major impact on the long term treatment costs associated with diabetic care. - Obesity
- More than half of U.S. adults are overweight and nearly one-quarter of the U.S. adults are considered to be obese. The increasing prevalence of overweight and obesity is a major public health concern, since obesity is associated with several chronic diseases. For example, overweight and obesity are known risk factors for diabetes, heart disease, stroke, hypertension, gallbladder disease, osteoarthritis, sleep apnea, and some forms of cancer such as uterine, breast, colorectal, kidney, and gallbladder. Furthermore, obesity is associated with high cholesterol, complications of pregnancy, menstrual irregularities, hirsutism, and increased surgical risk.
- Drugs currently approved by the FDA for the treatment of obesity produce weight losses of about 10% of initial body weight at one year when used singly. Combination therapy with phentermine and fenfluramine produced weight losses of about 15% of initial body weight at one year. Phenylpropanolamine (PPA) is an over-the-counter drug that has not been tested for long term use and is recommended for use for only about 12 weeks. With the exception of PPA, all of these drugs require a physician's prescription and are generally quite expensive. Side effects occur with all these drugs. For example, the administration of fenfluramine and phentermine for the treatment of obesity resulted in cardiac valve damage in some patients and ultimately led to the withdrawal of fenfluramine from the market. Two of the newest drugs for the treatment of obesity have side effects that limit their use. Sibutramine increases blood pressure in a subset of patients, and orlistat may have unpleasant gastrointestinal side effects.
- The Role of Chromium Complexes in the Treatment of Insulin-Dependent Maladies
- Chromium picolinate is reported to produce modest weight loss and changes in body composition (Kaats, 1998, Cefalu, 1999). Chromium is a nutritionally essential trace element. The essentiality of chromium in the diet was established in 1959 by Schwartz, as cited inPresent Knowledge in Nutrition, page 571, fifth edition (1984, the Nutrition Foundation, Washington, D.C.). Chromium depletion is characterized by the disturbance of glucose, lipid and protein metabolism and by a shortened lifespan. Chromium is essential for optimal insulin activity in all known insulin-dependent systems (Boyle et al., Southern Med. J. 70:1449-1453, 1977). Insufficient dietary chromium has been linked to both maturity-onset diabetes and to cardiovascular disease.
- The principal energy sources for the body are glucose and fatty acids. Chromium depletion results in biologically ineffective insulin and compromised glucose metabolism. Under these conditions, the body must rely primarily on lipid metabolism to meet its energy requirements, resulting in the production of excessive amounts of acetyl-CoA and ketone bodies. Some of the documented acetyl-CoA is diverted to increased cholesterol biosynthesis, resulting in hypercholesterolemia. Diabetes mellitus is characterized in large part by glycosuria, hypercholesterolemia, and often ketoacidosis. The accelerated atherosclerotic process seen in diabetics is associated with hypercholesterolemia (Boyle et al., supra.).
- Dietary supplementation of chromium to normal individuals has been reported to lead to improvements in glucose tolerance, serum lipid concentrations, including high-density lipoprotein cholesterol, insulin and insulin binding (Anderson,Clin. Psychol. Biochem. 4:31-41, 1986). Supplemental chromium in the trivalent form, e.g. chromic chloride, is associated with improvements of risk factors associated with adult-onset (type 2) diabetes and cardiovascular disease.
- Chromium functions as a cofactor for insulin. It binds to the insulin receptor and potentiates many, and perhaps all, of its functions (Boyle et al., supra.). These functions include, but are not limited to, the regulation of carbohydrate and lipid metabolism. (Present Knowledge in Nutrition, supra. at p. 573-577). The introduction of inorganic chromium compounds per se into individuals is not particularly beneficial. Chromium must be converted endogenously into an organic complex or must be consumed as a biologically active molecule. Only about 0.5% of ingested inorganic chromium is assimilated into the body (Recommended Daily Allowances, Ninth Revised Edition, The National Academy of Sciences, page 160, 1980). Only 1-2% of most organic chromium compounds are assimilated into the body.
- U.S. Pat. No. Re. 33,988 discloses that when selected essential metals, including chromium, are administered to mammals as exogenously synthesized coordination complexes of picolinic acid, they are directly available for absorption without competition from other metals. This patent describes a composition and method for selectively supplementing the essential metals in the human diet and for facilitating absorption of these metals by intestinal cells. These complexes are safe, inexpensive, biocompatible and easy to produce. These exogenously synthesized essential metal coordination complexes of picolinic acid (pyridine-2-carboxylic acid) have the following structural formula:
- wherein M represents the metallic cation and n is equal to the cation's valence. For example, when M is Cr and n=3, then the compound is chromic tripicolinate. Other chromium picolinates disclosed include chromic monopicolinate and chromic dipicolinate.
- The U.S. Recommended Daily Intake (RDI) of chromium is 120 μg. U.S. Pat. No. 5,087,623, the entire contents of which are hereby incorporated by reference, describes the administration of chromic tripicolinate for the treatment of adult-onset diabetes in doses ranging from 50 to 500 μg. International Patent Application No. WO96/35421 discloses the use of high doses of chromic tripicolinate (providing 1,000-10,000 μg chromium/day) for reducing hyperglycemia and stabilizing the level of serum glucose in humans with type 2 diabetes. U.S. Pat. No. 5,789,401 discloses achromic tripicolinate-biotin composition and its use in lowering blood glucose levels in humans with type 2 diabetes.
- U.S. Pat. Nos. 5,087,623; 5,087,624; and 5,175,156, the entire contents of which are hereby incorporated by reference, disclose the use of chromium tripicolinate for supplementing dietary chromium, reducing hyperglycemia and stabilizing serum glucose, increasing lean body mass and reducing body fat, and controlling blood serum lipid levels, including the lowering of undesirably high blood serum LDL-cholesterol levels and the raising of blood serum HDL-cholesterol levels. U.S. Pat. Nos. 4,954,492 and 5,194,615, the entire contents of which are hereby incorporated by reference, describe a related complex, chromic nicotinate, which is also used for supplementing dietary chromium and lowering serum lipid levels. Picolinic acid and nicotinic acid are position isomers having the following structures:
- Nicotinic acid and picolinic acid form coordination complexes with monovalent, divalent and trivalent metal ions and facilitate the absorption of these metals by transporting them across intestinal cells and into the bloodstream. Chromium absorption in rats following oral administration of CrCl3 was facilitated by the non-steroidal anti-inflammatory drugs (NSAIDs) aspirin and indomethacin (Davis et al., J. Nutrition Res. 15:202-210, 1995; Kamath et al., J. Nutrition 127:478-482, 1997). These drugs inhibit the enzyme cyclooxygenase which converts arachidonic acid to various prostaglandins, resulting in inhibition of intestinal mucus formation and lowering of intestinal pH which facilitates chromium absorption.
- Additional pharmacological treatments for disorders caused by or exacerbated by improper glucose uptake are needed. Specifically, compositions for the treatment of diabetes and obesity would be a great boon to subjects suffering from these disease states. A new, more effective, less expensive treatment for diabetes and obesity with minimal side effects would be a great benefit to the treatment and prevention of obesity.
- FIG. 1 shows the effect of conjugated linoleic acid (CLA) on glucose uptake in human skeletal muscle culture.
- FIG. 2 graphs the effect of CP+CLA on glucose uptake in human skeletal muscle culture.
- FIG. 3 illustrates the effect of CP+CLA on glucose uptake in human skeletal muscle culture.
- The disclosed invention is directed to compositions and methods for treating insulin-dependent diabetes, non-insulin dependent diabetes, reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia. One embodiment of the disclosed invention is a composition that includes at least one chromium complex and a conjugated fatty acid or conjugated fatty alcohol. Preferably, the chromium complex is chromium picolinate or chromium nicotinate. Advantageously, the conjugated fatty acid is conjugated linoleic acid.
- In one aspect of the invention, the composition optionally includes a chelating agent. The chelating agent may be picolinic acid, nicotinic acid, or both.
- The recited compositions are incorporated into a pharmaceutically effective carrier. The pharmaceutically effective carrier may be a tablet, capsule, microbead, emulsion, powder, granule, suspension, syrup or elixir. Preferably, when the carrier is a microbead, the microbead is a sugar beadlet or microcrystalline cellulose beadlet. Advantageously, the chromium complex and conjugated linoleic acid are coated on the beadlet. Optionally, the tablet, capsule, or microbead is coated with an enteric coating.
- In another aspect of the invention, the chromium complex and conjugated fatty acid or conjugated fatty alcohol are in a ratio of between about 1:666 to about 1:200 (w/w).
- Additional components may be included in the composition. For example, the composition may include at least one of a cyclooxygenase inhibitor, a mucolytic, or a salicin-containing herb. The cyclooxygenase inhibitor may be indomethacin, ibuprofen, acetaminophen, or naproxen. Advantageously, the salicin-containing herb may includeBoswellia serrata (frankincense), Betula lenta (sweet birch), Betula pubescens (white birch), Filipendula ulmaria (meadowsweet), Gautheria procumbens (wintergreens), Polulus balsamifera, Populus jackii (balm of Gilead) and Salix alba (white willow). The mucolytic may be guaifenesin.
- Embodiments of the invention provide a method of treating
type 1 diabetes in a subject. The method of treatment includes administering to a subject a pharmaceutically effective dose of a conjugated fatty acid or conjugated fatty alcohol in conjunction with at least one chromium complex. The chromium complex may be chromium picolinate, chromium nicotinate, chromic tripicolinate, chromic polynicotinate, chromium chloride, chromium histidinate, or chromium yeasts. Optionally, the composition further includes at least one chelating agent. The chelating agent may be picolinic acid, nicotinic acid, or both. - A method of treating obesity in a subject is similarly contemplated. The method of treatment includes administering to a subject a pharmaceutically effective dose of conjugated fatty acid or conjugated fatty alcohol in conjunction with at least one chromium complex. The chromium complex may be chromium picolinate, chromium nicotinate, chromic tripicolinate, chromic polynicotinate, chromium chloride, chromium histidinate, or chromium yeasts. Optionally, the composition further includes at least one chelating agent. The chelating agent may be picolinic acid, nicotinic acid, or both.
- The disclosed invention relates to compositions for the treatment of
type 1 diabetes. In particular, these compositions can be administered to reduce or even eliminate the need for administration of insulin in certain patients withtype 1 diabetes. Further, they are used in methods for facilitating glucose uptake and utilization by cells. Certain individuals with type 2 diabetes will require insulin. The invention also relates to the treatment of type 2 diabetics who require insulin. Additionally, methods for treating obesity and increasing lean body mass are likewise contemplated. A primary basis of the present invention is the novel and unexpected discovery that compositions comprising an effective dose of a chromium complex in combination with a conjugated fatty acid or conjugated fatty alcohol produce a synergistic effect on glucose uptake in a subject in need thereof. Additionally, the co-administration of a chromium complex with a conjugated fatty acid or conjugated fatty alcohol, or an isomer thereof, demonstrate a synergistic, weight loss effect. - The terminology used in the description presented herein is not intended to be interpreted in any limited or restrictive manner, simply because it is being utilized in conjunction with a detailed description of certain specific embodiments of the invention. Furthermore, embodiments of the invention may include several novel features, no single one of which is solely responsible for its desirable attributes or which is essential to practicing the invention herein described.
- The term “conjugated compound” refers to a compound having at least a portion that is a hydrocarbon, with at least three consecutive carbon-carbon bonds, such that single and double carbon-carbon bonds are found in an alternating manner. Thus, the compound will include the subunit C═C—C═C (hydrogens and other substituents not shown). Two preferred categories of conjugated compounds are fatty acids and fatty alcohols. It should be noted that these di- or poly-unsaturated compounds are referred to herein using the common names of the corresponding naturally-occurring compounds having the same number of carbons and unsaturations. Although such naturally-occurring compounds are not necessarily conjugated, due to the arrangement of their carbon-carbon double bonds, it will be understood in the context of the present invention that only conjugated versions of those compounds are contemplated; i.e., the arrangement of the double bounds will be such that they contain the substructure C═C—C═C. While compounds having as few as 4, 5, 6, or 7 carbon atoms are contemplated, the preferred conjugated compounds have 8, 9, 10, 12, 14, 16 or more carbon atoms, preferably not more than 32, 30, 28, or 26 carbon atoms. It should be noted that the phrase “conjugated fatty acid” or “conjugated fatty alcohol,” as used herein, also includes isomers of fatty acids and fatty alcohols, as well as any other polyunsaturated compounds which act synergistically with chromium complexes to promote glucose uptake in a subject in need thereof Suitable conjugated fatty acids include, without limitation, conjugated versions of linoleic acid, linolenic acid, gamma linolenic acid, arachidonic acid, mead acid, stearidonic acid, alpha-eleostearic acid, eleostearic acid, pinolenic acid, docosatetraenoic acid, 9,12-octadecadienoic acid, octadecatrienoic acid, eicosatetraenoic acid, eicosapentaenoic acid, docosahexaenoic acid, docosapentaenoic acid, and all other diunsaturated and polyunsaturated fatty acids. In a preferred embodiment, the conjugated fatty acid is conjugated linoleic acid (CLA). As used herein, the phrase “conjugated fatty alcohols” includes, without limitation, conjugated versions of linoleic alcohol, linolenic alcohol, gamma linolenic alcohol, arachidonic alcohol, mead alcohol, stearidonic alcohol alpha-eleostearic alcohol, eleostearic alcohol, pinolenic alcohol, docosadienic alcohol, docosatetraenoic alcohol, octadecadienoic alcohol, octadecatrienoic alcohol, eicosatetraenoic alcohol, cicosapentaenoic alcohol, docosahexaenoic alcohol, docosapentaenoic alcohol, and all other diunsaturated and polyunsaturated fatty alcohols. The present invention further includes the use of other conjugated compounds having at least 4, 5, 6, 7, or 8 carbon atoms, that functions synergistically with a chromium complex to facilitate glucose uptake and usage by cells. (Such function can be readily assayed, as further described below.) Note that the present invention includes alcohols and acids in which one or more of the double bonds result in a cis isomer, as well as those in which one or more of the double bonds result in a trans isomer. In some cases, all the double bonds are cis, while in others they are all trans, and in still other cases they are mixed cis and trans compounds.
- In a preferred embodiment, the conjugated fatty acid of the composition is conjugated linoleic acid. Conjugated linoleic acid (CLA) has been reported in numerous publications to reduce fat gain in growing animals by 25%-70% (Park et al., 1997). Minimal studies have been performed on human subjects. In a preliminary study by Atkinson et al., there was no effect of CLA alone in obese subjects when added to standard diet and exercise. However, a subgroup of subjects who did not follow the diet and exercise program well, and who gained lean body mass, had a reduction in fat mass in the CLA subjects and an increase in fat mass in placebo subjects (Atkinson, communication, 2000). These data, along with the animal data, suggest that CLA is most effective in preventing fat accumulation rather than producing fat loss. Two hypotheses have been advanced to explain the role of CLA in weight loss: 1) CLA may act as a β-3 agonist; and 2) CLA alters nutrient partitioning within muscles to promote fat oxidation rather than carbohydrate (CHO) oxidation (Park et al., 1999).
- Embodiments of the present invention include compositions which contain a conjugated fatty acid or conjugated fatty alcohol in combination with at least one chromium complex. Additionally, uses of the compositions disclosed herein to treat diabetes and/or obesity are provided. The co-administration of a conjugated fatty acid or conjugated fatty alcohol and at least one chromium complex provides a number of advantages over conventional pharmaceutical regimes for the treatment of diabetes and promotion of weight loss. One advantage of the compositions described herein over conventional treatment regimes for diabetes (such as injection of insulin) and weight loss is that compositions comprising a conjugated compound such as a conjugated fatty acid or conjugated fatty alcohol and at least one chromium complex have no known side effects while still providing efficacy in glucose uptake and weight loss. With reference to FIG. 1, one will observe that a conjugated fatty acid such as CLA alone had no effect on glucose uptake in human skeletal muscle culture under both basal (without insulin) and stimulated (with insulin) conditions. The units referred to on the vertical axis of FIGS. 1 and 2 are pico Moles per milligram of glucose uptake. The unit referred to on the vertical axis of FIG. 3 is the percentage increase in the uptake of glucose in human skeletal muscle culture. The term Basal as used in FIGS. 1 and 2 refers to human skeletal muscle culture without insulin. Whereas the term Stimulated indicates human skeletal muscle culture with insulin. Those bars on FIGS. 1, 2, and3 representing Chromium Picolinate (CP) and Conjugated Linoleic Acid (CLA) are measured in nanograms per milliliter.
- However, the administration of CLA in combination with a chromium complex such as chromium picolinate (CP) (as depicted in FIG. 2) significantly increases glucose uptake in human skeletal muscle culture under both basal (without insulin) and stimulated (with insulin) conditions. CP and CLA under basal conditions was shown to have a greater effect than insulin alone.
- Finally, turning to FIG. 3, it will be appreciated that CLA plus a chromium complex synergistically aid in the percent increase in the uptake of glucose in human skeletal muscle culture.
- In some embodiments, compositions comprising an effective dose of a chromium complex are provided. As used herein, the terms “chromium complexes” or “chromium complex” include, without limitation, chromium picolinate, chromic tripicolinate, chromium nicotinate, chromic polynicotinate, chromium chloride, chromium histidinate, and chromium yeasts. Chromium picolinate, for example, has been shown to produce modest weight loss and changes in body composition.
- The compositions of the disclosed invention additionally include an effective dose of conjugated compound such as a conjugated fatty acid or conjugated fatty alcohol, of the type previously described. In preferred embodiments, the conjugated fatty acid component of the composition is linoleic acid (CLA). Suitable forms of CLA include isomers with double bonds at carbons 9, 11;
carbons - While the chromium complexes aid in the absorption of chromium by intestinal cells, in some embodiments, chelating agents are advantageously included in the compositions to facilitate absorption of other ingested chromium as well as other metals including, but not limited to, copper, iron, magnesium, manganese and zinc. Suitable chelating agents include picolinic acid, nicotinic acid, or both picolinic acid and nicotinic acid. Thus, the compositions of the disclosed invention are readily absorbable forms of chromium which also facilitate absorption of other essential metals in the human diet.
- The chromium complexes of the disclosed invention have the same uses as described for chromic tripicolinate in U.S. Pat. Nos. 5,087,623, 5,087,624 and 5,174,156, namely supplementing dietary chromium, lowering blood glucose levels in diabetics, lowering serum lipid levels and increasing lean body mass. Additionally, the chromium complexes of the present invention act to treat symptoms associated with overweight and obesity.
- Advantageously, the chromium complexes are synthetic. The synthesis and use of chromium picolinates is described in U.S. Pat. No. Re. 33,988 and U.S. Pat. No. 5,087,623. Chromic tripicolinate is available from health food stores, drug stores and other commercial sources. The synthesis and use of chromic polynicotinate is described in U.S. Pat. No. 5,194,615.
- The chelating agents such as picolinic acid and nicotinic acid are available from many commercial sources, including Sigma-Aldrich (St. Louis, Mo.) (picolinic acid; catalog No. P5503; nicotinic acid; catalog No. PN4126). Preferably, the ratio of the chromium complex to the chelating agent from about 10:1 to about 1:10 (w/w), more preferably from about 5:1 to about 1:5 (w/w).
- A variety of delivery systems are available to deliver the compositions to a subject in need thereof. Preferably, the compositions of the disclosed invention are prepared by incorporating the components into a pharmaceutically acceptable carrier, including but not limited to tablets, capsules and microbeads, preferably sugar beadlets or microcrystalline cellulose.
- For oral administration, the chromium complex may be incorporated into a tablet, aqueous or oil suspension, dispersible powder or granule, microbead, emulsion, hard or soft capsule, syrup or elixir. The components of the composition may also be administered separately. Compositions may be prepared according to any method known in the art for the manufacture of pharmaceutically acceptable compositions and such compositions may contain one or more of the following agents: sweeteners, flavoring agents, coloring agents and preservatives. Tablets containing the active ingredients in admixture with non-toxic pharmaceutically acceptable excipients suitable for tablet manufacture are acceptable. “Pharmaceutically acceptable” means that the agent should be acceptable in the sense of being compatible with the other ingredients of the formulation (as well as non-injurious to the individual). Such excipients include inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, such as corn starch and alginic acid; binding agents such as starch, gelatin or acacia; and lubricating agents such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or may be coated with known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period of time. For example, a time delay material such as glyceryl monostearate or glyceryl stearate alone or with a wax may be employed.
- In another preferred embodiment, tablets, capsules or microbeads are coated with an enteric coating which prevents dissolution in the acidic environment of the stomach. Instead, this coating dissolves in the small intestine at a more neutral pH. Because certain chromium complexes may be more stable at this neutral pH than at the acidic pH of the stomach, enhanced absorption occurs because the chromium complexes remain substantially intact until they reach the small intestine. Such enteric coated compositions are described by Bauer et al.,Coated Pharmaceutical Dosage Forms: Fundamentals, Manufacturing Techniques, Biopharmaceutical Aspects, Test Methods and Raw Materials, CRC Press, Washington, D.C., 1998, the entire contents of which are hereby incorporated by reference.
- Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
- Aqueous suspensions may contain the chromium complexes of the invention in admixture with excipients for the manufacture of aqueous suspensions. Such excipients include suspending agents, dispersing or wetting agents, one or more preservatives, one or more coloring agents, one or more flavoring agents and one or more sweetening agents such as sucrose or saccharin.
- Oil suspensions may be formulated by suspending the active ingredient in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oil suspension may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol. Sweetening agent, such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by an added antioxidant such as ascorbic acid. Dispersible powders and granules of the invention suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, and one or more preservatives. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
- Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
- The oral formulations described above may also include aspirin (acetylsalicylic acid), other salicylates, or another NSAID such as indomethacin, ibuprofen, acetaminophen, naproxen or any drug capable of inhibiting the cyclooxygenase pathway leading to prostaglandin synthesis. This results in a decrease in intestinal mucus production and lower intestinal pH which facilitates absorption of the chromium compositions of the present invention. The oral compositions may further include mucolytics such as guaifenesin and the like, to inhibit intestinal mucus production, and/or acids such as ascorbic acid, citric acid and the like to lower intestinal pH. Inclusion of one or both of these compounds further enhances chromium absorption. There are two forms of cyclooxygenase (cox), cox1 and cox2, which differ in their sensitivity to inhibition by NSAIDs. The cox2 isozyme promotes prostaglandin formation at sites of inflammation, but not at other sites such as the gastrointestinal tract. In contrast, relatively selective inhibition of
cox 1 facilitates chromic tripicolinate and chromic polynicotinate absorption. Although the selective inhibition of cox1 is desirable, any inhibitor or cox1 or cox2 can be formulated with the chromic tripicolinate and chromic polynicotinate compositions of the invention. Cox inhibitors, acids and mucolytics may also be coadministered with the chromic tripicolinate and chromic polynicotinate compositions of the invention. The amount of these drugs formulated with or coadministered with the chromic tripicolinate compositions of the invention are as follows: cox inhibitions, between about 50 mg and 500 mg; mucolytics, between about 10 mg and 250 mg; and acids, between about 50 mg and about 1,000 mg. - The coadministration or formulation of salicylate-containing herbs with the compositions of the invention is also contemplated. Class I herbs, as documented in the American Herbal Products Association'sBotanical Safety Handbook (herbs that can be safely consumed when used appropriately), such as Boswelia serrata (frankincense), Betula lenta (sweet birch), Betula pubescens (white birch), Filipendula ulmaria (meadowsweet), Gaultheria procumbens (wintergreens), Populus balsamifera and Populus jackii (balm of Gilead), and Salix alba (white willow) are all salicin-containing plants with salicylate-like properties. These herbs suppress prostaglandin synthesis by cox inhibition, thereby improving absorption of the chromium complexes of the invention. These herbs are relatively free from gastric ulcerogenic effects (Singh et al., Agents and Actions 18:407-412, 1986). In addition, pre-clinical acute toxicity studies have shown that salicin-containing plants do not cause hematological disturbances (American Herbal Products Association, Botanical Safety Handbook, 1997).
- The compounds and herbs described above all effect gut physiology by inhibiting prostaglandin synthesis, decreasing mucus production, and lowering gastrointestinal pH. The inclusion of these compounds, as well as an enteric coating, into the oral chromium picolinate or chromium nicotinate compositions of the invention results in a multicomponent delivery system which allows delivery of these agents to the gastrointestinal tract where they work in concert to facilitate chromium absorption.
- In a preferred embodiment, the chromium complex is coated onto microbeads. In a particularly preferred embodiment, these microbeads are sugar beadlets of various sizes, also known as nonpareils, and are commercially available from, for example, SmithKline Beecham. If the microbeads are to be used to administer the compositions of the invention to diabetic patients, the administration of other types of microbeads, such as microcrystalline cellulose, is preferred. Microcrystalline cellulose is commercially available and can be processed into beadlets of various sizes by micronization, a technique well known in the art. The microbeads are essentially a carrier for the compositions of the invention. For a description of coated beadlets, see, for example, Carstensen, I. T.,Pharmaceutical Principles of Solid Dosage Forms, Technonic Publishing Co., Inc., Lancaster, Pa., pp. 228-230, 1993, hereby incorporated by reference. Aqueous solutions containing the chromium complexes with or without the chelating agent components such as nicotinic acid and picolinic acid are sprayed onto the microbeads by well known methods. by suspending the microbeads in an up current of air and introducing a fine spray of the active ingredients which form a coating on the outside of the microbeads which is then allowed to dry. The desired chromium complex components with or without a chelating agent may be combined into one same solution or applied using separate solutions. Optionally, the coated microbeads can be further coated with a substance to protect the active ingredients coated onto the beads, such as latex. The microbeads may be placed in a capsule prior to administration. In another preferred embodiment, the capsule or the microbeads are coated with an enteric coating to delay dissolution until reaching the small intestine.
- Typically, the dosage range of chromium administered to an individual in the form of chromium picolinate, chromium nicotinate, or other chromium complex provides between about 50 and 10,000 micrograms per day of chromium; preferably between about 100 and 1,000 micrograms per day; more preferably, between about 200 and 500 micrograms per day.
- In some embodiments, methods of increasing glucose uptake by cells or by organisms, such as mammals and humans, treating insulin-dependent diabetes, reducing body fat, improving insulin sensitivity, reducing hyperglycemia, and reducing hypercholesterolemia with chromium complexes and conjugated compounds such as conjugated fatty acids or conjugated fatty alcohols are contemplated and isomers of fatty acids, as well as isomers of fatty alcohols. Advantageously, a subject is administered a pharmaceutically effective dose of a chromium complex. In one embodiment, the conjugated compound is administered substantially simultaneously with the chromium complex. In an alternative embodiment, the chromium complex is administered first and then the conjugated compound is added second. In yet another embodiment, the conjugated compound is administered first. Preferably, the chromium complex and conjugated compound are administered to a subject within twenty-four hours of each other. In a particularly preferred embodiment, the chromium complex and conjugated compound are administered within an hour of each other.
- The following examples teach certain methods and compositions for treating diabetes and obesity through the administration of at least one chromium complex in concert with a conjugated compound. The subject can advantageously be a vertebrate, a mammal, a bird, and is preferably a human, a cat, or a dog. It will be appreciated, however, that the at least one chromium complex may be administered first, then the conjugated compound. Alternatively, the conjugated compound can be administered first, then the chromium complex. As illustrated in the following examples, the composition may optionally include picolinic acid, nicotinic acid, or both picolinic acid and nicotinic acid in combination with a chromium complex and conjugated compound. These examples are illustrative only and are not intended to limit the scope of the invention disclosed herein. The treatment methods described below can be optimized using empirical techniques well known to those of ordinary skill in the art. Moreover, artisans of skill would be able to use the teachings described in the following examples to practice the full scope of the invention disclosed herein.
- An obese adult human subject is identified. The subject is orally administered a tablet containing about 300 μg chromium as chromium picolinate and 1 gram conjugated linoleic acid twice a day. The tablet additionally comprises ibuprofen in a pharmaceutically effective dose of 200 mg. Over the course of several weeks, a decrease in body mass is observed. The chromium picolinate in combination with conjugated linoleic acid synergistically reduce the subject's body mass.
- It will be appreciated that although specific embodiments of the invention have been described herein for the purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.
- A subject suffering from insulin-dependent diabetes is identified. The subject is orally administered a daily dose of one tablet containing about 500 μg chromium as chromium nicotinate and 500 mg conjugated linoleic acid. Over the course of several days, an improvement in glucose uptake in the subject is observed and insulin dependence is reduced. The chromium nicotinate in combination with linoleic acid act synergistically to improve the subject's glucose tolerance and to treat the subject's diabetes.
Claims (60)
1. A method of treating obesity in a subject in need thereof comprising:
identifying a subject presenting with obesity;
administering to said subject a pharmaceutically effective dose of a conjugated fatty acid or conjugated fatty alcohol in combination with a pharmaceutically effective dose of at least one chromium complex selected from the group consisting of chromium picolinate, chromium nicotinate, chromic tripicolinate, chromic polynicotinate, chromium chloride, chromium histidinate, and chromium yeasts.
2. The method of claim 1 , wherein said conjugated fatty acid is selected from the group consisting of a conjugated version of linoleic acid, linolenic acid, gamma linolenic acid, arachidonic acid, mead acid, stearidonic acid, alpha-eleostearic acid, eleostearic acid, pinolenic acid, docosadienic acid, docosatetraenoic acid, octadecadienoic acid, octadecatrienoic acid, eicosatetraenoic acid, eicosapentaenoic acid, docosahexaenoic acid, and docosapentaenoic acid.
3. The method of claim 1 , wherein said conjugated fatty acid is conjugated linoleic acid.
4. The method of claim 1 , wherein said conjugated fatty alcohol is selected from the group consisting of a conjugated version of linoleic alcohol, linolenic alcohol, gamma linolenic alcohol, arachidonic alcohol, mead alcohol, stearidonic alcohol, alpha-eleostearic alcohol, eleostearic alcohol, pinolenic alcohol, docosadienic alcohol, docosatetraenoic alcohol, octadecadienoic alcohol, octadecatrienoic alcohol, eicosatetraenoic alcohol, eicosapentaenoic alcohol, docosahexaenoic alcohol, docosapentaenoic alcohol, and all other diunsaturated and polyunsaturated fatty alcohols.
5. The method of claim 1 , wherein said composition further comprises at least one uncomplexed chelating agent.
6. The method of claim 5 , wherein said chelating agent is picolinic acid, nicotinic acid, or both.
7. The method of claim 1 , wherein said composition further comprises at least one of a cyclooxygenase inhibitor, a mucolytic, and a salicin-containing herb.
8. The method of claim 1 , wherein said at least one cyclooxygenase inhibitor is selected from the group consisting of indomethacin, ibuprofen, acetaminophen, and naproxen.
9. The method of claim 7 , wherein said salicin-containing herb is selected from the group consisting of Boswellia serrata (frankincense), Betula lenta (sweet birch), Betula pubescens (white birch), Filipendula ulmaria (meadowsweet), Gautheria procumbens (wintergreens), Polulus balsamifera, Populus jackii (balm of Gilead) and Salix alba (white willow).
10. The method of claim 7 , wherein said mucolytic is guaifenesin.
11. A method of reducing body fat comprising administering to a subject in need of body fat reduction a pharmaceutically effective dose of a conjugated fatty acid or conjugated fatty alcohol in conjunction with a pharmaceutically effective dose of at least one chromium complex selected from the group consisting of chromium picolinate, chromium nicotinate, chromic tripicolinate, chromic polynicotinate, chromium chloride, chromium histidinate, and chromium yeasts.
12. The method of claim 11 , wherein said conjugated fatty acid is selected from the group consisting of a conjugated version of linoleic acid, linolenic acid, gamma linolenic acid, arachidonic acid, mead acid, stearidonic acid, alpha-eleostearic acid, eleostearic acid, pinolenic acid, docosadienic acid, docosatetraenoic acid, octadecadienoic acid, octadecatrienoic acid, eicosatetraenoic acid, eicosapentaenoic acid, docosahexaenoic acid, and docosapentaenoic acid.
13. The method of claim 11 , wherein said conjugated fatty acid is conjugated linoleic acid.
14. The method of claim 11 , wherein said conjugated fatty alcohol is selected from the group consisting of a conjugated version of linoleic alcohol, linolenic alcohol, gamma linolenic alcohol, arachidonic alcohol, mead alcohol, stearidonic alcohol, alpha-eleostearic alcohol, eleostearic alcohol, pinolenic alcohol, docosadienic alcohol, docosatetraenoic alcohol, octadecadienoic alcohol, octadecatrienoic alcohol, eicosatetraenoic alcohol, eicosapentaenoic alcohol, docosahexaenoic alcohol, docosapentaenoic alcohol, and all other diunsaturated and polyunsaturated fatty alcohols.
15. The method of claim 11 , wherein said composition further comprises at least one uncomplexed chelating agent.
16. The method of claim 15 , wherein said chelating agent is picolinic acid, nicotinic acid, or both.
17. The method of claim 11 , wherein said composition further comprises at least one of a cyclooxygenase inhibitor, a mucolytic, and a salicin-containing herb.
18. The method of claim 17 , wherein said at least one cyclooxygenase inhibitor is selected from the group consisting of indomethacin, ibuprofen, acetaminophen, and naproxen.
19. The method of claim 17 , wherein said salicin-containing herb is selected from the group consisting of Boswellia serrata (frankincense), Betula lenta (sweet birch), Betula pubescens (white birch), Filipendula ulmaria (meadowsweet), Gautheria procumbens (wintergreens), Polulus balsamifera, Populus jackii (balm of Gilead) and Salix alba (white willow).
20. The method of claim 17 , wherein said mucolytic is guaifenesin.
21. A method of improving insulin sensitivity in a subject in need thereof comprising administering to said subject a pharmaceutically effective dose of a conjugated fatty acid or conjugated fatty alcohol in conjunction with at least one chromium complex selected from the group consisting of chromium picolinate, chromium nicotinate, chromic tripicolinate, chromic polynicotinate, chromium chloride, chromium histidinate, and chromium yeasts.
22. The method of claim 21 , wherein said conjugated fatty acid is selected from the group consisting of a conjugated version of linoleic acid, linolenic acid, gamma linolenic acid, arachidonic acid, mead acid, stearidonic acid, alpha-eleostearic acid, eleostearic acid, pinolenic acid, docosadienic acid, docosatetraenoic acid, octadecadienoic acid, octadecatrienoic acid, eicosatetraenoic acid, eicosapentaenoic acid, docosahexaenoic acid, and docosapentaenoic acid.
23. The method of claim 21 , wherein said conjugated fatty acid is conjugated linoleic acid.
24. The method of claim 21 , wherein said conjugated fatty alcohol is selected from the group consisting of a conjugated version of linoleic alcohol, linolenic alcohol, gamma linolenic alcohol, arachidonic alcohol, mead alcohol, stearidonic alcohol, alpha-eleostearic alcohol, eleostearic alcohol, pinolenic alcohol, docosadienic alcohol, docosatetraenoic alcohol, octadecadienoic alcohol, octadecatrienoic alcohol, eicosatetraenoic alcohol, eicosapentaenoic alcohol, docosahexaenoic alcohol, and docosapentaenoic alcohol.
25. The method of claim 21 , wherein said composition further comprises at least one uncomplexed chelating agent.
26. The method of claim 25 , wherein said chelating agent is picolinic acid, nicotinic acid, or both.
27. The method of claim 21 , wherein said composition further comprises at least one of a cyclooxygenase inhibitor, a mucolytic, and a salicin-containing herb.
28. The method of claim 27 , wherein said at least one cyclooxygenase inhibitor is selected from the group consisting of indomethacin, ibuprofen, acetaminophen, and naproxen.
29. The method of claim 27 , wherein said salicin-containing herb is selected from the group consisting of Boswellia serrata (frankincense), Betula lenta (sweet birch), Betula pubescens (white birch), Filipendula ulmaria (meadowsweet), Gautheria procumbens (wintergreens), Polulus balsamifera, Populus jackii (balm of Gilead) and Salix alba (white willow).
30. The method of claim 27 , wherein said mucolytic is guaifenesin.
31. A method of reducing hyperglycemia in a subject in need thereof comprising administering to said subject a pharmaceutically effective dose of a conjugated fatty acid or conjugated fatty alcohol in conjunction with at least one chromium complex selected from the group consisting of chromium picolinate, chromium nicotinate, chromic tripicolinate, chromic polynicotinate, chromium chloride, chromium histidinate, and chromium yeasts.
32. The method of claim 31 , wherein said conjugated fatty acid is selected from the group consisting of a conjugated version of linoleic acid, linolenic acid, gamma linolenic acid, arachidonic acid, mead acid, stearidonic acid, alpha-eleostearic acid, eleostearic acid, pinolenic acid, docosadienic acid, docosatetraenoic acid, octadecadienoic acid, octadecatrienoic acid, eicosatetraenoic acid, eicosapentaenoic acid, docosahexaenoic acid, and docosapentaenoic acid.
33. The method of claim 31 , wherein said conjugated fatty acid is conjugated linoleic acid.
34. The method of claim 31 , wherein said conjugated fatty alcohol is selected from the group consisting of a conjugated version of linoleic alcohol, linolenic alcohol, gamma linolenic alcohol, arachidonic alcohol, mead alcohol, stearidonic alcohol, alpha-eleostearic alcohol, eleostearic alcohol, pinolenic alcohol, docosadienic alcohol, docosatetraenoic alcohol, octadecadienoic alcohol, octadecatrienoic alcohol, eicosatetraenoic alcohol, eicosapentaenoic alcohol, docosahexaenoic alcohol, and docosapentaenoic alcohol.
35. The method of claim 31 , wherein said composition further comprises at least one uncomplexed chelating agent.
36. The method of claim 35 , wherein said chelating agent is picolinic acid, nicotinic acid, or both.
37. The method of claim 31 , wherein said composition further comprises at least one of a cyclooxygenase inhibitor, a mucolytic, and a salicin-containing herb.
38. The method of claim 37 , wherein said at least one cyclooxygenase inhibitor is selected from the group consisting of indomethacin, ibuprofen, acetaminophen, and naproxen.
39. The method of claim 37 , wherein said salicin-containing herb is selected from the group consisting of Boswellia serrata (frankincense), Betula lenta (sweet birch), Betula pubescens (white birch), Filipendula ulmaria (meadowsweet), Gautheria procumbens (wintergreens), Polulus balsamifera, Populus jackii (balm of Gilead) and Salix alba (white willow).
40. The method of claim 37 , wherein said mucolytic is guaifenesin.
41. A method of reducing hypercholesterolemia in a subject in need thereof comprising administering to said subject a pharmaceutically effective dose of a conjugated fatty acid or conjugated fatty alcohol in conjunction with at least one chromium complex selected from the group consisting of chromium picolinate, chromium nicotinate, chromic tripicolinate, chromic polynicotinate, chromium chloride, chromium histidinate, and chromium yeasts.
42. The method of claim 41 , wherein said conjugated fatty acid is selected from the group consisting of a conjugated version of linoleic acid, linolenic acid, gamma linolenic acid, arachidonic acid, mead acid, stearidonic acid, alpha-eleostearic acid, eleostearic acid, pinolenic acid, docosadienic acid, docosatetraenoic acid, octadecadienoic acid, octadecatrienoic acid, eicosatetraenoic acid, eicosapentaenoic acid, docosahexaenoic acid, and docosapentaenoic acid.
43. The method of claim 41 , wherein said conjugated fatty acid is conjugated linoleic acid.
44. The method of claim 41 , wherein said conjugated fatty alcohol is selected from the group consisting of a conjugated version of linoleic alcohol, linolenic alcohol, gamma linolenic alcohol, arachidonic alcohol, mead alcohol, stearidonic alcohol, alpha-eleostearic alcohol, eleostearic alcohol, pinolenic alcohol, docosadienic alcohol, docosatetraenoic alcohol, octadecadienoic alcohol, octadecatrienoic alcohol, eicosatetraenoic alcohol, eicosapentaenoic alcohol, docosahexaenoic alcohol, and docosapentaenoic alcohol.
45. The method of claim 41 , wherein said composition further comprises at least one uncomplexed chelating agent.
46. The method of claim 45 , wherein said chelating agent is picolinic acid, nicotinic acid, or both.
47. The method of claim 41 , wherein said composition further comprises at least one of a cyclooxygenase inhibitor, a mucolytic, and a salicin-containing herb.
48. The method of claim 47 , wherein said at least one cyclooxygenase inhibitor is selected from the group consisting of indomethacin, ibuprofen, acetaminophen, and naproxen.
49. The method of claim 47 , wherein said salicin-containing herb is selected from the group consisting of Boswellia serrata (frankincense), Betula lenta (sweet birch), Betula pubescens (white birch), Filipendula ulmaria (meadowsweet), Gautheria procumbens (wintergreens), Polulus balsamifera, Populus jackii (balm of Gilead) and Salix alba (white willow).
50. The method of claim 47 , wherein said mucolytic is guaifenesin.
51. A method of promoting weight loss in a subject in need thereof comprising administering to said subject a pharmaceutically effective dose of a conjugated fatty acid or conjugated fatty alcohol in conjunction with at least one chromium complex selected from the group consisting of chromium picolinate, chromium nicotinate, chromic tripicolinate, chromic polynicotinate, chromium chloride, chromium histidinate, and chromium yeasts.
52. The method of claim 51 , wherein said conjugated fatty acid is selected from the group consisting of a conjugated version of linoleic acid, linolenic acid, gamma linolenic acid, arachidonic acid, mead acid, stearidonic acid, alpha-eleostearic acid, eleostearic acid, pinolenic acid, docosadienic acid, docosatetraenoic acid, octadecadienoic acid, octadecatrienoic acid, eicosatetraenoic acid, eicosapentaenoic acid, docosahexaenoic acid, and docosapentaenoic acid.
53. The method of claim 51 , wherein said conjugated fatty acid is conjugated linoleic acid.
54. The method of claim 51 , wherein said conjugated fatty alcohol is selected from the group consisting of a conjugated version of linoleic alcohol, linolenic alcohol, gamma linolenic alcohol, arachidonic alcohol, mead alcohol, stearidonic alcohol, alpha-eleostearic alcohol, eleostearic alcohol, pinolenic alcohol, docosadienic alcohol, docosatetraenoic alcohol, octadecadienoic alcohol, octadecatrienoic alcohol, eicosatetraenoic alcohol, eicosapentaenoic alcohol, docosahexaenoic alcohol, and docosapentaenoic alcohol.
55. The method of claim 51 , wherein said composition further comprises at least one uncomplexed chelating agent.
56. The method of claim 55 , wherein said chelating agent is picolinic acid, nicotinic acid, or both.
57. The method of claim 51 , wherein said composition further comprises at least one of a cyclooxygenase inhibitor, a mucolytic, and a salicin-containing herb.
58. The method of claim 57 , wherein said at least one cyclooxygenase inhibitor is selected from the group consisting of indomethacin, ibuprofen, acetaminophen, and naproxen.
59. The method of claim 57 , wherein said salicin-containing herb is selected from the group consisting of Boswellia serrata (frankincense), Betula lenta (sweet birch), Betula pubescens (white birch), Filipendula ulmaria (meadowsweet), Gautheria procumbens (wintergreens), Polulus balsamifera, Populus jackii (balm of Gilead) and Salix alba (white willow).
60. The method of claim 57 , wherein said mucolytic is guaifenesin.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/319,328 US20030091654A1 (en) | 2000-09-21 | 2002-12-12 | Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
US11/435,125 US20090136539A9 (en) | 2000-09-21 | 2006-05-16 | Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
US11/435,120 US20090060941A9 (en) | 2000-09-21 | 2006-05-16 | Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23447400P | 2000-09-21 | 2000-09-21 | |
US29668801P | 2001-06-06 | 2001-06-06 | |
US09/957,876 US6809115B2 (en) | 2000-09-21 | 2001-09-20 | Methods and compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
US10/319,328 US20030091654A1 (en) | 2000-09-21 | 2002-12-12 | Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/957,876 Division US6809115B2 (en) | 2000-09-21 | 2001-09-20 | Methods and compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/435,125 Continuation US20090136539A9 (en) | 2000-09-21 | 2006-05-16 | Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
US11/435,120 Continuation US20090060941A9 (en) | 2000-09-21 | 2006-05-16 | Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030091654A1 true US20030091654A1 (en) | 2003-05-15 |
Family
ID=26927971
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/957,876 Expired - Lifetime US6809115B2 (en) | 2000-09-21 | 2001-09-20 | Methods and compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
US10/319,328 Abandoned US20030091654A1 (en) | 2000-09-21 | 2002-12-12 | Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
US11/435,125 Abandoned US20090136539A9 (en) | 2000-09-21 | 2006-05-16 | Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
US11/435,120 Abandoned US20090060941A9 (en) | 2000-09-21 | 2006-05-16 | Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/957,876 Expired - Lifetime US6809115B2 (en) | 2000-09-21 | 2001-09-20 | Methods and compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/435,125 Abandoned US20090136539A9 (en) | 2000-09-21 | 2006-05-16 | Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
US11/435,120 Abandoned US20090060941A9 (en) | 2000-09-21 | 2006-05-16 | Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
Country Status (9)
Country | Link |
---|---|
US (4) | US6809115B2 (en) |
EP (1) | EP1357977B1 (en) |
JP (1) | JP2004509143A (en) |
CN (1) | CN1665566A (en) |
AT (1) | ATE271406T1 (en) |
AU (1) | AU2001294602A1 (en) |
DE (1) | DE60104450T2 (en) |
ES (1) | ES2223924T3 (en) |
WO (1) | WO2002024180A2 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030008845A1 (en) * | 2001-05-31 | 2003-01-09 | Cook Mark E. | Conjugated nonadecadienoic acid compositions |
US20050019416A1 (en) * | 2002-04-11 | 2005-01-27 | Ocean Nutrition Canada Ltd. | Encapsulated agglomeration of microcapsules and method for the preparation thereof |
US20050067726A1 (en) * | 2002-11-04 | 2005-03-31 | Nianxi Yan | Microcapsules having multiple shells and method for the preparation thereof |
US20050147588A1 (en) * | 2003-11-17 | 2005-07-07 | Chih-Ping Liu | Methods for treatment of obesity and for promotion of weight loss |
US20060165990A1 (en) * | 2005-01-21 | 2006-07-27 | Curtis Jonathan M | Microcapsules and emulsions containing low bloom gelatin and methods of making and using thereof |
US20070269566A1 (en) * | 2006-05-17 | 2007-11-22 | Curtis Jonathan M | Homogenized formulations containing microcapsules and methods of making and using thereof |
US20080139649A1 (en) * | 2005-01-27 | 2008-06-12 | Barrow Colin J | Fatty Acid-Benzenediol Derivatives and Methods of Making and Using Thereof |
US20080206316A1 (en) * | 2005-01-27 | 2008-08-28 | Colin Barrow | Chromium-Fatty Acid Compounds and Methods of Making and Using Thereof |
KR100895800B1 (en) | 2005-01-31 | 2009-05-08 | 로더스 크로클란 비.브이. | Use of Pinolenic Acid |
US20100009015A1 (en) * | 2007-01-31 | 2010-01-14 | Vijaya Juturu | Use of chromium histidinate for treatment of cardiometabolic disorders |
US20100055281A1 (en) * | 2006-04-07 | 2010-03-04 | Ocean Nutrition Canada Limited | Emulsions and Microcapsules With Substances Having Low Interfacial Tension, Methods of Making and Using Thereof |
US20100173002A1 (en) * | 2006-06-05 | 2010-07-08 | Jin Yulai | Microcapsules with improved shells |
US8586061B2 (en) | 2007-06-26 | 2013-11-19 | Jds Therapeutics, Llc | Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement |
WO2014003741A1 (en) * | 2012-06-26 | 2014-01-03 | Young Living Essential Oils, Lc. | Frankincense chewing gum |
US8933022B2 (en) | 2011-03-01 | 2015-01-13 | Jds Therapeutics, Llc | Methods and compositions for the treatment and prevention Hypoglycemia and related disorders |
US9119835B2 (en) | 2007-03-13 | 2015-09-01 | JDS Therapeautics, LLC | Methods and compositions for the sustained release of chromium |
US11857553B2 (en) | 2016-02-11 | 2024-01-02 | Nutrition21, LLC | Chromium containing compositions for improving health and fitness |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7927636B1 (en) * | 1997-07-14 | 2011-04-19 | Interhealth Nutraceuticals, Inc. | Hydroxycitric acid compositions, pharmaceutical and dietary supplements and food products made therefrom, and methods for their use in reducing body weight |
US20030228347A1 (en) * | 2000-09-12 | 2003-12-11 | Clark George H. | Amino acid chelate for the effective supplementation of calcium magnesium and potassium in the human diet |
US20040157929A1 (en) * | 2002-04-01 | 2004-08-12 | Ohia Sunny E. | Method for increasing serotonin levels in a person by administration of a composition incorporating(-)hydroxycitric acid, and related compositions thereof |
US7119110B2 (en) * | 2001-10-05 | 2006-10-10 | Interhealth Nutraceuticals Incorporated | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
US6888016B2 (en) * | 2001-10-16 | 2005-05-03 | Loders Croklaan Usa Llc | Mixtures for stimulating glucose up-take |
US20030119913A1 (en) * | 2001-12-20 | 2003-06-26 | Ohia Sunny E. | Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof |
DE10226018A1 (en) * | 2002-06-12 | 2003-12-24 | Cognis Deutschland Gmbh | Preparations with conjugated linoleic alcohol |
AU2003242695B2 (en) * | 2002-07-01 | 2007-12-06 | Unilever Plc | Satiety inducing composition |
KR100523446B1 (en) * | 2002-08-23 | 2005-10-25 | 주식회사 엠디바이오알파 | Frankinsence extracts having activatory effects on 5' AMP-activated protin kinase |
IL152397A (en) * | 2002-10-21 | 2009-02-11 | Hadasit Med Res Service | Compositions and compounds for the treatment of hyperglycemia |
US20060171992A1 (en) * | 2002-12-20 | 2006-08-03 | Gerhardt Cinderella C | Blood glucose regulating composition |
US7759507B2 (en) * | 2003-09-05 | 2010-07-20 | Abbott Laboratories | Lipid system and methods of use |
US20060029642A1 (en) | 2004-08-03 | 2006-02-09 | Dusan Miljkovic | Methods and compositions for improved chromium complexes |
US7297686B2 (en) * | 2004-11-16 | 2007-11-20 | Hwang David L | Chromium complex with insulin-like activity |
GB0426264D0 (en) * | 2004-11-30 | 2004-12-29 | Trigen Ltd | Compounds |
US20070104805A1 (en) * | 2005-11-01 | 2007-05-10 | Udell Ronald G | Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives |
WO2007109845A1 (en) * | 2006-03-28 | 2007-10-04 | Medical Therapies Limited | Prophylaxis or treatment of diabetes |
CA2650342C (en) * | 2006-04-26 | 2014-09-16 | Mandrillus Pharma, Llc | Chromium complexes |
JP5045879B2 (en) * | 2006-06-07 | 2012-10-10 | 株式会社龍泉堂 | A mixture having an effect of improving insulin resistance, an effect of suppressing weight gain, and an effect of preventing and improving fatty liver |
EP2034983A1 (en) * | 2006-06-27 | 2009-03-18 | Lipid Nutrition B.V. | Use of a polyunsaturated fatty acid compound |
RU2009121007A (en) * | 2006-11-03 | 2010-12-10 | Пронова Биофарма Норге Ас (No) | FAT ALCOHOLS |
EP2124905B1 (en) | 2007-01-10 | 2016-09-07 | DSM Nutritional Products AG | Microcapsules including pea protein |
ITPD20070049A1 (en) * | 2007-02-14 | 2008-08-15 | Sila S R L | CONJUGATED LINOLEIC ACID PRODUCT AND PROCESS FOR ITS MANUFACTURE |
JP2010202634A (en) * | 2008-06-05 | 2010-09-16 | Green Kanpo Seiyaku Kk | Crude drug-containing composition and use thereof |
TWI454221B (en) * | 2008-07-14 | 2014-10-01 | Composition and method for inhibiting formation of body fat | |
WO2010105239A1 (en) * | 2009-03-13 | 2010-09-16 | Russell Kenneth O | Method for enhancing insulin mediated uptake of nutrients into cells |
ES2739976T3 (en) * | 2009-07-01 | 2020-02-05 | Jds Therapeutics Llc | Chromium complexes as brain glucose transporter enhancers |
AU2011349715A1 (en) * | 2010-12-21 | 2013-07-04 | Nestec S.A. | Methods and compositions suitable for managing blood glucose in animals |
CN103082298B (en) * | 2013-01-17 | 2014-08-13 | 吉林省中药制剂工程研究中心有限公司 | Health-care food for reducing blood glucose in assisted mode and preparation method thereof |
CA2990230A1 (en) | 2015-06-19 | 2016-12-22 | University Of Southern California | Compositions and methods for modified nutrient delivery |
US10744070B2 (en) | 2015-06-19 | 2020-08-18 | University Of Southern California | Enteral fast access tract platform system |
EA031455B1 (en) * | 2015-08-03 | 2019-01-31 | Республиканское Государственное Предприятие На Праве Хозяйственного Ведения "Северо-Казахстанский Государственный Университет Имени Манаша Козыбаева" | Emulsion medicinal product |
EP3429625B1 (en) * | 2016-03-15 | 2023-04-26 | Queen Mary University of London | Method of treatment of obesity |
US10820617B1 (en) | 2018-03-29 | 2020-11-03 | Government Of The United States, As Represented By The Secretary Of The Air Force | All inclusive electrolytes, vitamins, and protein powder training supplement |
CN111568889A (en) * | 2020-06-12 | 2020-08-25 | 四川大学华西医院 | Application of hydroxyoctadecadienoic acid in preparation of alpha-glucosidase inhibitor drugs and separation method thereof |
CN115245510A (en) * | 2021-04-28 | 2022-10-28 | 扬州大学 | Application of trans-10, cis-12 conjugated linoleic acid |
Citations (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3899476A (en) * | 1974-04-29 | 1975-08-12 | Westvaco Corp | Process for making a methacrylic acid adduct of linoleic acid and product |
US3923765A (en) * | 1972-10-04 | 1975-12-02 | Wacker Chemie Gmbh | Process for suspension polymerization of vinyl halides with low polymer deposition |
US4056637A (en) * | 1976-06-08 | 1977-11-01 | Japan Natural Food Co. Ltd. | Process for preparing food products containing a lactic acid bacteria-fermented product of a cereal germ |
US4393043A (en) * | 1980-01-25 | 1983-07-12 | Societe Anonyme Dite L'oreal | Solutions containing at least one essential fatty acid and vegetable oil, and cosmetic compositions containing these solutions |
US4407821A (en) * | 1980-09-24 | 1983-10-04 | Roussel Uclaf | Lipidic compositions for use in dietetics, reanimation and therapeutics |
US4871768A (en) * | 1984-07-12 | 1989-10-03 | New England Deaconess Hospital Corporation | Dietary supplement utilizing ω-3/medium chain trigylceride mixtures |
US4954492A (en) * | 1983-07-08 | 1990-09-04 | The William Seroy Group | Synthetic GTF chromium material for decreasing blood lipid levels and process therefor |
US5017614A (en) * | 1989-02-17 | 1991-05-21 | Wisconsin Alumni Research Foundation | Methods of preventing oxidation, quenching singlet oxygen and inhibiting mold growth and novel compositions therefor |
US5053534A (en) * | 1990-10-11 | 1991-10-01 | Westvaco Corporation | Process for making a dicarboxylic acid |
US5070104A (en) * | 1989-02-17 | 1991-12-03 | Wisconsin Alumni Research Foundation | Methods of chelating metal and novel compositions therefor |
US5087624A (en) * | 1989-03-21 | 1992-02-11 | Nutrition 21 | Chromic picolinate treatment |
US5087623A (en) * | 1988-05-31 | 1992-02-11 | Nitrition 21 | Chromic picolinate treatment |
USRE33988E (en) * | 1980-08-08 | 1992-07-07 | The United States of America as repesented by the Secretary of Agriculture | Dietary supplementation with essential metal picolinates |
US5175156A (en) * | 1987-11-30 | 1992-12-29 | Nutrition 21 | Chromic picolinate treatment |
US5194615A (en) * | 1983-07-08 | 1993-03-16 | The William Seroy Group | Synthetic GTF chromium nicotinate material and its preparation |
US5194640A (en) * | 1991-06-10 | 1993-03-16 | Westvaco Corporation | Process for making high-purity oleic acid |
US5208356A (en) * | 1989-02-17 | 1993-05-04 | Wisconsin Alumni Research Foundation | Octadecadienoic phospholipic esters, antioxidant and mold inhibiting compositions |
US5292538A (en) * | 1992-07-22 | 1994-03-08 | Metagenics, Inc. | Improved sustained energy and anabolic composition and method of making |
US5428072A (en) * | 1992-04-29 | 1995-06-27 | Wisconsin Alumni Research Foundation | Method of increasing the efficiency of feed conversion in animals |
US5430066A (en) * | 1992-04-29 | 1995-07-04 | Wisconsin Alumni Research Foundation | Methods for preventing weight loss, reduction in weight gain, and anorexia due to immune stimulation |
US5543405A (en) * | 1993-10-22 | 1996-08-06 | Keown; Wendy J. | Composition and method for weight reduction and long term management of obesity |
US5554646A (en) * | 1992-04-29 | 1996-09-10 | Wisconsin Alumni Research Foundation | Method for reducing body fat in animals |
US5626849A (en) * | 1995-06-07 | 1997-05-06 | Reliv International, Inc. | Weight loss composition for burning and reducing synthesis of fats |
US5760082A (en) * | 1994-08-29 | 1998-06-02 | Wisconsin Alumni Research Foundation | Dietetic foods containing conjugated linoleic acids |
US5770247A (en) * | 1996-10-03 | 1998-06-23 | Wisconsin Alumni Research Foundation | Method of increasing the CLA content of cow's milK |
US5789401A (en) * | 1997-08-08 | 1998-08-04 | Nutrition 21 | High-dose chromium/biotin treatment of type II diabetes |
US5804210A (en) * | 1996-08-07 | 1998-09-08 | Wisconsin Alumni Research Foundation | Methods of treating animals to maintain or enhance bone mineral content and compositions for use therein |
US5814663A (en) * | 1994-08-29 | 1998-09-29 | Wisconsin Alumni Research Foundation | Method for maintaining an existing level of body fat |
US5837733A (en) * | 1997-02-26 | 1998-11-17 | Wisconsin Alumni Research Foundation | Method for reducing secetion of apolipoprotein B in animals by administering conjugated linoleic acid |
US5851572A (en) * | 1997-04-25 | 1998-12-22 | Wisconsin Alumni Research Foundation | Method of increasing fat firmness and improving meat quality in animals with conjugated linolenic acid |
US5855917A (en) * | 1996-12-04 | 1999-01-05 | Wisconsin Alumni Research Foundation | Method for controlling body fat and/or body weight in animals and pharmaceutical compositions for use therein comprising 20-carbon conjugated unsaturated fatty acids |
US5855949A (en) * | 1994-01-10 | 1999-01-05 | Mclean; Linsey | Dietary system high in oil intake |
US5856149A (en) * | 1995-06-01 | 1999-01-05 | Wisconsin Alumni Research Foundation | Method of producing conjugated fatty acids |
US5892074A (en) * | 1997-02-18 | 1999-04-06 | Seidel; Michael C. | Synthesis of conjugated linoleic acid (CLA) |
US5980905A (en) * | 1998-08-28 | 1999-11-09 | Ambi Inc. | Chromium polynicotinate compositions and uses thereof |
US5986115A (en) * | 1996-08-20 | 1999-11-16 | Schering Ag | 7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents |
US6015833A (en) * | 1998-03-17 | 2000-01-18 | Conlinco., Inc. | Conjugated linoleic acid compositions |
US6019874A (en) * | 1999-01-19 | 2000-02-01 | Berg; Lloyd | Separation of conjugated linoleic acids by azeotropic distillation |
US6020377A (en) * | 1998-03-13 | 2000-02-01 | Kansas State University Research Foundation | Modified tall oil supplemented diet for growing-finishing pigs |
US6020376A (en) * | 1995-06-01 | 2000-02-01 | Wisconsin Alumni Research Foundation | Methods of treating animals to maintain or increase CD-4 and CD-8 cell populations |
US6034132A (en) * | 1998-01-05 | 2000-03-07 | Natural Nutrition Ltd. As | Method of reducing bodyweight and treating obesity |
US6042869A (en) * | 1998-02-20 | 2000-03-28 | Natural Nutrition Ltd. | Bulk animal feeds containing conjugated linoleic acid |
US6060514A (en) * | 1998-05-04 | 2000-05-09 | Conlin Co., Inc. | Isomer enriched conjugated linoleic acid compositions |
US6060087A (en) * | 1997-04-25 | 2000-05-09 | Wisconsin Alumni Research Foundation | Method of increasing fat firmness and improving meat quality in animals |
US6077525A (en) * | 1998-04-10 | 2000-06-20 | The George Washington University | Use of conjugated linoleic acids |
US6093711A (en) * | 1998-08-28 | 2000-07-25 | Ambi Inc. | Enteric-coated chromium picolinate compositions and uses thereof |
US6153774A (en) * | 1997-02-18 | 2000-11-28 | Seidel; Michael C. | Silver ion chromatography of high purity conjugated linoleic acid (CLA) |
US6159525A (en) * | 1995-11-14 | 2000-12-12 | Van Den Bergh Foods Co., Division Of Conopco, Inc. | Edible fat-spread |
US6177580B1 (en) * | 1998-04-21 | 2001-01-23 | Henkel Kommanditgesellschaft Auf Aktien | Conjugated linolenic acid-based synthetic triglycerides |
US6184009B1 (en) * | 1995-11-14 | 2001-02-06 | Loders Croklaan B.V. | Process for the preparation of materials with a high content of conjugated long chain polyunsaturated fatty acids |
US6214372B1 (en) * | 1998-05-04 | 2001-04-10 | Con Lin Co., Inc. | Method of using isomer enriched conjugated linoleic acid compositions |
US6225486B1 (en) * | 1998-05-04 | 2001-05-01 | Conlinco, Inc. | Isomer enriched conjugated linoleic acid compositions |
US6342619B2 (en) * | 1999-04-01 | 2002-01-29 | Michael C. Seidel | Synthesis of conjugated fatty acid |
US6413545B1 (en) * | 1998-09-01 | 2002-07-02 | Access Business Group International Llc | Diet composition and method of weight management |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3923768A (en) | 1974-11-18 | 1975-12-02 | Westvaco Corp | Treatment of tall oil fatty acids |
CA2011410C (en) * | 1990-03-02 | 1996-12-31 | Mikio Suzuki | Method for continuous casting of steel |
US5890905A (en) * | 1995-01-20 | 1999-04-06 | Bergman; Marilyn M. | Educational and life skills organizer/memory aid |
FR2729957B1 (en) | 1995-01-31 | 1997-12-05 | Maurel Sante | ORGANOMETALLIC COMPLEXES BASED ON SITOSTEROLS AND ACYLGLYCEROLS AND PHARMACEUTICAL COMPOSITIONS AND DIETETIC PRODUCTS CONTAINING SAME. |
US6329361B1 (en) | 1995-05-12 | 2001-12-11 | Nutrition 21 | High-dose chromic picolinate treatment of type II diabetes |
JP3017108B2 (en) | 1996-10-30 | 2000-03-06 | リノール油脂株式会社 | Method for producing conjugated linoleic acid |
WO1998033494A1 (en) | 1997-02-04 | 1998-08-06 | Kosbab John V | Compositions and methods for prevention and treatment of vascular degenerative diseases |
US6113973A (en) | 1998-04-15 | 2000-09-05 | Wisconsin Alumni Research Foundation | Eggs enriched with conjugated linoleic acid |
US6132724A (en) * | 1998-04-29 | 2000-10-17 | City Of Hope National Medical Center | Allelic polygene diagnosis of reward deficiency syndrome and treatment |
FI111513B (en) | 1998-05-06 | 2003-08-15 | Raisio Benecol Oy | Novel compositions of phytosterol and phytostanol fatty acid esters, products containing them and processes for their preparation |
US6020378A (en) | 1999-03-30 | 2000-02-01 | Wisconsin Alumni Research Foundation | Method for selectively altering body fat level, feed efficiently, or weight gain |
PL354684A1 (en) * | 1999-12-16 | 2004-02-09 | Harry Siskind | Nutritional composition, methods of producing said composition and methods of using said composition |
US7208522B1 (en) | 2000-08-02 | 2007-04-24 | Pharmanutrients | Methods and compositions for the prevention and treatment of Syndrome X |
AU2000265108A1 (en) | 2000-08-02 | 2002-02-13 | Pharmanutrients | Methods and compositions for the attenuation and/or prevention of stress/catabolic responses |
WO2002009693A1 (en) | 2000-08-02 | 2002-02-07 | Pharmanutrients | Method and compositions for prevention and/or treatment of diabetes and glucose modulation |
WO2002009725A1 (en) | 2000-08-02 | 2002-02-07 | Pharmanutrients | Methods and compositions for the prevention and treatment of inflamation, osteoarthritis, and other degenerative joint diseases |
-
2001
- 2001-09-20 ES ES01975262T patent/ES2223924T3/en not_active Expired - Lifetime
- 2001-09-20 CN CN018189342A patent/CN1665566A/en active Pending
- 2001-09-20 DE DE60104450T patent/DE60104450T2/en not_active Expired - Lifetime
- 2001-09-20 AU AU2001294602A patent/AU2001294602A1/en not_active Abandoned
- 2001-09-20 JP JP2002528216A patent/JP2004509143A/en active Pending
- 2001-09-20 AT AT01975262T patent/ATE271406T1/en not_active IP Right Cessation
- 2001-09-20 US US09/957,876 patent/US6809115B2/en not_active Expired - Lifetime
- 2001-09-20 EP EP01975262A patent/EP1357977B1/en not_active Expired - Lifetime
- 2001-09-20 WO PCT/US2001/029422 patent/WO2002024180A2/en active IP Right Grant
-
2002
- 2002-12-12 US US10/319,328 patent/US20030091654A1/en not_active Abandoned
-
2006
- 2006-05-16 US US11/435,125 patent/US20090136539A9/en not_active Abandoned
- 2006-05-16 US US11/435,120 patent/US20090060941A9/en not_active Abandoned
Patent Citations (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3923765A (en) * | 1972-10-04 | 1975-12-02 | Wacker Chemie Gmbh | Process for suspension polymerization of vinyl halides with low polymer deposition |
US3899476A (en) * | 1974-04-29 | 1975-08-12 | Westvaco Corp | Process for making a methacrylic acid adduct of linoleic acid and product |
US4056637A (en) * | 1976-06-08 | 1977-11-01 | Japan Natural Food Co. Ltd. | Process for preparing food products containing a lactic acid bacteria-fermented product of a cereal germ |
US4393043A (en) * | 1980-01-25 | 1983-07-12 | Societe Anonyme Dite L'oreal | Solutions containing at least one essential fatty acid and vegetable oil, and cosmetic compositions containing these solutions |
USRE33988E (en) * | 1980-08-08 | 1992-07-07 | The United States of America as repesented by the Secretary of Agriculture | Dietary supplementation with essential metal picolinates |
US4407821A (en) * | 1980-09-24 | 1983-10-04 | Roussel Uclaf | Lipidic compositions for use in dietetics, reanimation and therapeutics |
US4954492A (en) * | 1983-07-08 | 1990-09-04 | The William Seroy Group | Synthetic GTF chromium material for decreasing blood lipid levels and process therefor |
US5194615A (en) * | 1983-07-08 | 1993-03-16 | The William Seroy Group | Synthetic GTF chromium nicotinate material and its preparation |
US4871768A (en) * | 1984-07-12 | 1989-10-03 | New England Deaconess Hospital Corporation | Dietary supplement utilizing ω-3/medium chain trigylceride mixtures |
US5175156A (en) * | 1987-11-30 | 1992-12-29 | Nutrition 21 | Chromic picolinate treatment |
US5087623A (en) * | 1988-05-31 | 1992-02-11 | Nitrition 21 | Chromic picolinate treatment |
US5017614A (en) * | 1989-02-17 | 1991-05-21 | Wisconsin Alumni Research Foundation | Methods of preventing oxidation, quenching singlet oxygen and inhibiting mold growth and novel compositions therefor |
US5070104A (en) * | 1989-02-17 | 1991-12-03 | Wisconsin Alumni Research Foundation | Methods of chelating metal and novel compositions therefor |
US5208356A (en) * | 1989-02-17 | 1993-05-04 | Wisconsin Alumni Research Foundation | Octadecadienoic phospholipic esters, antioxidant and mold inhibiting compositions |
US5087624A (en) * | 1989-03-21 | 1992-02-11 | Nutrition 21 | Chromic picolinate treatment |
US5053534A (en) * | 1990-10-11 | 1991-10-01 | Westvaco Corporation | Process for making a dicarboxylic acid |
US5194640A (en) * | 1991-06-10 | 1993-03-16 | Westvaco Corporation | Process for making high-purity oleic acid |
US5428072A (en) * | 1992-04-29 | 1995-06-27 | Wisconsin Alumni Research Foundation | Method of increasing the efficiency of feed conversion in animals |
US5430066A (en) * | 1992-04-29 | 1995-07-04 | Wisconsin Alumni Research Foundation | Methods for preventing weight loss, reduction in weight gain, and anorexia due to immune stimulation |
US5554646A (en) * | 1992-04-29 | 1996-09-10 | Wisconsin Alumni Research Foundation | Method for reducing body fat in animals |
US5292538A (en) * | 1992-07-22 | 1994-03-08 | Metagenics, Inc. | Improved sustained energy and anabolic composition and method of making |
US5543405A (en) * | 1993-10-22 | 1996-08-06 | Keown; Wendy J. | Composition and method for weight reduction and long term management of obesity |
US5855949A (en) * | 1994-01-10 | 1999-01-05 | Mclean; Linsey | Dietary system high in oil intake |
US5814663A (en) * | 1994-08-29 | 1998-09-29 | Wisconsin Alumni Research Foundation | Method for maintaining an existing level of body fat |
US5760082C1 (en) * | 1994-08-29 | 2001-03-06 | Wisconsin Alumni Res Found | Dietetic foods containing conjugated linoleic acids |
US5760082A (en) * | 1994-08-29 | 1998-06-02 | Wisconsin Alumni Research Foundation | Dietetic foods containing conjugated linoleic acids |
US6020376A (en) * | 1995-06-01 | 2000-02-01 | Wisconsin Alumni Research Foundation | Methods of treating animals to maintain or increase CD-4 and CD-8 cell populations |
US5856149A (en) * | 1995-06-01 | 1999-01-05 | Wisconsin Alumni Research Foundation | Method of producing conjugated fatty acids |
US5626849A (en) * | 1995-06-07 | 1997-05-06 | Reliv International, Inc. | Weight loss composition for burning and reducing synthesis of fats |
US6159525A (en) * | 1995-11-14 | 2000-12-12 | Van Den Bergh Foods Co., Division Of Conopco, Inc. | Edible fat-spread |
US6184009B1 (en) * | 1995-11-14 | 2001-02-06 | Loders Croklaan B.V. | Process for the preparation of materials with a high content of conjugated long chain polyunsaturated fatty acids |
US5804210A (en) * | 1996-08-07 | 1998-09-08 | Wisconsin Alumni Research Foundation | Methods of treating animals to maintain or enhance bone mineral content and compositions for use therein |
US5986115A (en) * | 1996-08-20 | 1999-11-16 | Schering Ag | 7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents |
US5770247A (en) * | 1996-10-03 | 1998-06-23 | Wisconsin Alumni Research Foundation | Method of increasing the CLA content of cow's milK |
US5855917A (en) * | 1996-12-04 | 1999-01-05 | Wisconsin Alumni Research Foundation | Method for controlling body fat and/or body weight in animals and pharmaceutical compositions for use therein comprising 20-carbon conjugated unsaturated fatty acids |
US5892074A (en) * | 1997-02-18 | 1999-04-06 | Seidel; Michael C. | Synthesis of conjugated linoleic acid (CLA) |
US6153774A (en) * | 1997-02-18 | 2000-11-28 | Seidel; Michael C. | Silver ion chromatography of high purity conjugated linoleic acid (CLA) |
US5837733A (en) * | 1997-02-26 | 1998-11-17 | Wisconsin Alumni Research Foundation | Method for reducing secetion of apolipoprotein B in animals by administering conjugated linoleic acid |
US6060087A (en) * | 1997-04-25 | 2000-05-09 | Wisconsin Alumni Research Foundation | Method of increasing fat firmness and improving meat quality in animals |
US5851572A (en) * | 1997-04-25 | 1998-12-22 | Wisconsin Alumni Research Foundation | Method of increasing fat firmness and improving meat quality in animals with conjugated linolenic acid |
US5789401A (en) * | 1997-08-08 | 1998-08-04 | Nutrition 21 | High-dose chromium/biotin treatment of type II diabetes |
US6034132A (en) * | 1998-01-05 | 2000-03-07 | Natural Nutrition Ltd. As | Method of reducing bodyweight and treating obesity |
US6203843B1 (en) * | 1998-02-20 | 2001-03-20 | Natural Nutrition Ltd. | Bulk animal feeds containing conjugated linoleic acid |
US6042869A (en) * | 1998-02-20 | 2000-03-28 | Natural Nutrition Ltd. | Bulk animal feeds containing conjugated linoleic acid |
US6020377A (en) * | 1998-03-13 | 2000-02-01 | Kansas State University Research Foundation | Modified tall oil supplemented diet for growing-finishing pigs |
US6015833A (en) * | 1998-03-17 | 2000-01-18 | Conlinco., Inc. | Conjugated linoleic acid compositions |
US6077525A (en) * | 1998-04-10 | 2000-06-20 | The George Washington University | Use of conjugated linoleic acids |
US6177580B1 (en) * | 1998-04-21 | 2001-01-23 | Henkel Kommanditgesellschaft Auf Aktien | Conjugated linolenic acid-based synthetic triglycerides |
US6060514A (en) * | 1998-05-04 | 2000-05-09 | Conlin Co., Inc. | Isomer enriched conjugated linoleic acid compositions |
US6214372B1 (en) * | 1998-05-04 | 2001-04-10 | Con Lin Co., Inc. | Method of using isomer enriched conjugated linoleic acid compositions |
US6225486B1 (en) * | 1998-05-04 | 2001-05-01 | Conlinco, Inc. | Isomer enriched conjugated linoleic acid compositions |
US6242621B1 (en) * | 1998-05-04 | 2001-06-05 | Conlinco., Inc. | Isomer enriched conjugated linoleic acid compositions |
US6333353B2 (en) * | 1998-05-04 | 2001-12-25 | Conlinco, Inc. | Isomer enriched conjugated linoleic acid compositions |
US5980905A (en) * | 1998-08-28 | 1999-11-09 | Ambi Inc. | Chromium polynicotinate compositions and uses thereof |
US6093711A (en) * | 1998-08-28 | 2000-07-25 | Ambi Inc. | Enteric-coated chromium picolinate compositions and uses thereof |
US6413545B1 (en) * | 1998-09-01 | 2002-07-02 | Access Business Group International Llc | Diet composition and method of weight management |
US6019874A (en) * | 1999-01-19 | 2000-02-01 | Berg; Lloyd | Separation of conjugated linoleic acids by azeotropic distillation |
US6342619B2 (en) * | 1999-04-01 | 2002-01-29 | Michael C. Seidel | Synthesis of conjugated fatty acid |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6908946B2 (en) * | 2001-05-31 | 2005-06-21 | Wisconsin Alumni Research Foundation | Conjugated nonadecadienoic acid compositions |
US20030008845A1 (en) * | 2001-05-31 | 2003-01-09 | Cook Mark E. | Conjugated nonadecadienoic acid compositions |
US20050019416A1 (en) * | 2002-04-11 | 2005-01-27 | Ocean Nutrition Canada Ltd. | Encapsulated agglomeration of microcapsules and method for the preparation thereof |
US7727629B2 (en) | 2002-04-11 | 2010-06-01 | Ocean Nutrition Canada Limited | Encapsulated agglomeration of microcapsules and method for the preparation thereof |
US20100092571A1 (en) * | 2002-11-04 | 2010-04-15 | Nianxi Yan | Microcapsules having multiple shells and method for the preparation thereof |
US20050067726A1 (en) * | 2002-11-04 | 2005-03-31 | Nianxi Yan | Microcapsules having multiple shells and method for the preparation thereof |
US8900630B2 (en) | 2002-11-04 | 2014-12-02 | Dsm Nutritional Products | Microcapsules having multiple shells and method for the preparation thereof |
US20110111020A1 (en) * | 2002-11-04 | 2011-05-12 | Ocean Nutrition Canada Limited | Microcapsules Having Multiple Shells and Method for the Preparation Thereof |
US20050147588A1 (en) * | 2003-11-17 | 2005-07-07 | Chih-Ping Liu | Methods for treatment of obesity and for promotion of weight loss |
US20060165990A1 (en) * | 2005-01-21 | 2006-07-27 | Curtis Jonathan M | Microcapsules and emulsions containing low bloom gelatin and methods of making and using thereof |
US8034450B2 (en) | 2005-01-21 | 2011-10-11 | Ocean Nutrition Canada Limited | Microcapsules and emulsions containing low bloom gelatin and methods of making and using thereof |
US20080206316A1 (en) * | 2005-01-27 | 2008-08-28 | Colin Barrow | Chromium-Fatty Acid Compounds and Methods of Making and Using Thereof |
US20080139649A1 (en) * | 2005-01-27 | 2008-06-12 | Barrow Colin J | Fatty Acid-Benzenediol Derivatives and Methods of Making and Using Thereof |
KR100895800B1 (en) | 2005-01-31 | 2009-05-08 | 로더스 크로클란 비.브이. | Use of Pinolenic Acid |
US20090274791A1 (en) * | 2005-07-07 | 2009-11-05 | Mattson Pete H | Food Articles With Delivery Devices and Methods for the Preparation Thereof |
US20100055281A1 (en) * | 2006-04-07 | 2010-03-04 | Ocean Nutrition Canada Limited | Emulsions and Microcapsules With Substances Having Low Interfacial Tension, Methods of Making and Using Thereof |
US9968120B2 (en) | 2006-05-17 | 2018-05-15 | Dsm Nutritional Products Ag | Homogenized formulations containing microcapsules and methods of making and using thereof |
US20070269566A1 (en) * | 2006-05-17 | 2007-11-22 | Curtis Jonathan M | Homogenized formulations containing microcapsules and methods of making and using thereof |
US9056058B2 (en) | 2006-06-05 | 2015-06-16 | Dsm Nutritional Products | Microcapsules with improved shells |
US20100173002A1 (en) * | 2006-06-05 | 2010-07-08 | Jin Yulai | Microcapsules with improved shells |
US20100009015A1 (en) * | 2007-01-31 | 2010-01-14 | Vijaya Juturu | Use of chromium histidinate for treatment of cardiometabolic disorders |
US9675702B2 (en) | 2007-03-13 | 2017-06-13 | Jds Therapeutics, Llc | Methods and compositions for the sustained release of chromium |
US9119835B2 (en) | 2007-03-13 | 2015-09-01 | JDS Therapeautics, LLC | Methods and compositions for the sustained release of chromium |
US9597404B2 (en) | 2007-03-13 | 2017-03-21 | Jds Therapeutics, Llc | Methods and compositions for sustained release of chromium |
US8586061B2 (en) | 2007-06-26 | 2013-11-19 | Jds Therapeutics, Llc | Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement |
US9421170B2 (en) | 2007-06-26 | 2016-08-23 | Jds Therapeutics, Llc | Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement |
US9005637B2 (en) | 2007-06-26 | 2015-04-14 | Jds Therapeutics, Llc | Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement |
US10363222B2 (en) | 2007-06-26 | 2019-07-30 | Jds Therapeutics, Llc | Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement |
US11241388B2 (en) | 2007-06-26 | 2022-02-08 | Jds Therapeutics, Llc | Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement |
US11801224B2 (en) | 2007-06-26 | 2023-10-31 | Jds Therapeutics, Llc | Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement |
US11850308B2 (en) | 2007-06-26 | 2023-12-26 | Bonafide Health, Llc | Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement |
US8933022B2 (en) | 2011-03-01 | 2015-01-13 | Jds Therapeutics, Llc | Methods and compositions for the treatment and prevention Hypoglycemia and related disorders |
WO2014003741A1 (en) * | 2012-06-26 | 2014-01-03 | Young Living Essential Oils, Lc. | Frankincense chewing gum |
US11857553B2 (en) | 2016-02-11 | 2024-01-02 | Nutrition21, LLC | Chromium containing compositions for improving health and fitness |
US11865121B2 (en) | 2016-02-11 | 2024-01-09 | Nutrition21, LLC | Chromium containing compositions for improving health and fitness |
Also Published As
Publication number | Publication date |
---|---|
JP2004509143A (en) | 2004-03-25 |
US20060204518A1 (en) | 2006-09-14 |
EP1357977B1 (en) | 2004-07-21 |
WO2002024180A3 (en) | 2003-04-24 |
DE60104450D1 (en) | 2004-08-26 |
US6809115B2 (en) | 2004-10-26 |
CN1665566A (en) | 2005-09-07 |
US20090060941A9 (en) | 2009-03-05 |
EP1357977A2 (en) | 2003-11-05 |
US20090136539A9 (en) | 2009-05-28 |
US20020081315A1 (en) | 2002-06-27 |
AU2001294602A1 (en) | 2002-04-02 |
ATE271406T1 (en) | 2004-08-15 |
ES2223924T3 (en) | 2005-03-01 |
DE60104450T2 (en) | 2005-09-15 |
WO2002024180A2 (en) | 2002-03-28 |
US20060204517A1 (en) | 2006-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6809115B2 (en) | Methods and compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols | |
US5948772A (en) | Chromium picolinate compositions and uses thereof | |
US5980905A (en) | Chromium polynicotinate compositions and uses thereof | |
US6323192B1 (en) | Chromium polynicotinate compositions and uses thereof for absorption of essential metals | |
US20020098247A1 (en) | Methods and compositions for the improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes and alpha lipoic acid | |
US6713469B2 (en) | Chromium picolinate compositions and uses thereof | |
EP1397148B1 (en) | Chromium/biotin treatment of dyslipidemia | |
WO2003043569A2 (en) | Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases | |
US20020086065A1 (en) | Methods and compositions for the benefit of those suffering from polycystic ovary syndrome with chromium complexes | |
US20210346334A1 (en) | Nutritional chromium compositions and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |
|
AS | Assignment |
Owner name: N21 ACQUISITION HOLDING, LLC, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NUTRITION 21, INC.;REEL/FRAME:027545/0079 Effective date: 20111122 |
|
AS | Assignment |
Owner name: JDS THERAPEUTICS, LLC, NEW YORK Free format text: CHANGE OF NAME;ASSIGNOR:N21 ACQUISITION HOLDING, LLC;REEL/FRAME:028603/0993 Effective date: 20120201 |